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General introduction Chapter 1
1.1 INTRODUCTION
At the moment there is a trend in dermatological health care toward more non-
invasive diagnostic methods and treatments. If non-invasive options become more 
implemented in the current clinical setting, this could cause a reduction of workload 
for dermatologists and costs of medical care might be reduced in the future. Diagnoses 
could be made in a ‘one-stop-shop’ setting and patients would become more self-
sufficient by treating themselves at home. Therefore, a non-invasive approach would 
be beneficial to caretakers and patients. In dermatology, basal cell carcinoma (BCC) 
is ideally suited for such an approach since it is a type of skin cancer with a benign 
growth character, a good prognosis and a negligible risk of metastasis. In this thesis 
we investigated options for non-invasive diagnosis and treatment of low risk basal cell 
carcinoma, paving the way toward implementation in clinical practice in the future.
Basal cell carcinoma
Epidemiology
Over the last decades, the incidence of skin cancer has been increasing worldwide. In 
the Netherlands, basal cell carcinoma (BCC) is the most prevalent form, with a lifetime 
risk of 16-20 per cent.(1, 2) Although the mortality is low, morbidity can be substantial 
in case of an aggressive local invasive growth pattern and due to its frequent localization 
in the head and neck area.(3)
For the rising incidence of BCC, ultraviolet light exposure is an important etiological 
factor. Increasing life-expectancy and recreational exposure to sunlight may explain 
the worldwide increase.(4) Genetic predisposition seems to be important in the 
development of BCC. Male sex, fair skin types I and II, immunosuppression and arsenic 
exposure are other recognized factors for the development of BCC.(1) BCCs can be 
classified with a ‘low risk profile’ or a ‘high risk profile’. The profile is determined by 
the tumour recurrence probability after treatment, which could be influenced by four 
prognostic factors: histopathological growth pattern, localisation, size and whether it 
is a primary or recurrent BCC.(5)
Pathogenesis
The vast majority of BCCs occur sporadically due to a genetic mutation that enhances 
sonic hedgehog (SHH) pathway signalling. In approximately 80% of sporadic BCCs, 
genetic mutations can be found in at least one allele of the tumour suppressor gene 
patched 1 (PTCH1), which acts as an primary inhibitor of the SHH-signalling pathway.(6, 7)
Cessation of the inhibition of the oncogene SMO caused by inactivating mutations of 
PTCH1 or loss of heterozygosity, leaves SMO in an activated state and downstream 
effectors are switched on (SUFU, GLI2), leading to enhanced cell proliferation and 
development of BCC (Fig. 1).(8) Furthermore, activating mutations in the oncogene 
smoothened (SMO) can cause BCC development.(9)
Figure 1. Hedgehog signalling pathway.
Figure reprinted with permission: Booms P, Harth M, Sader R, Ghanaati S. Vismodegib hedgehog-
signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic 
tumors in Gorlin syndrome. Ann Maxillofac Surg. 2015;5(1):14-9.
Clinical and histopathological presentation of BCC subtypes
A simplified histopathological classification of BCCs includes the following three 
subtypes: nodular, superficial and aggressive variants.(14) The most common subtype 
is nodular representing 40.6%-57.1% of the BCCs, followed by the superficial (19.5%-
30.7%) and the aggressive subtype(14.1%-28.7%).(14, 15)
Superficial BCCs are mainly located on the trunk and clinically show an erythematous 
and sometimes mildly squamous papule or plaque (Fig. 2A).(16) Histopathologically, 
these superficial BCCs are characterized by basaloid cells/nests that are attached to or 
lie in the epidermis.(17, 18)
Nodular BCCs clinically show erythematous papules or nodules with a pearly, shiny 
aspect and arborizing vessels (Fig. 2B). When the BCC enlarges, a typical central ulcer 
may appear (rodent ulcer).(16) Histopathology presents large nests of basaloid cells in 
the papillary or reticular dermis.(17, 18)
Aggressive BCC subtypes include the morpheaform/infiltrative, micronodular, and 
basosquamous BCC.(16) This type of BCC is clinically difficult to diagnose, since it does 
not have the typical clinical appearance. It usually appears as a pink to red plaque with 
ill-defined margins (Fig. 2C).(18)
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Figure 2. A. Superficial BCC,   B. Nodular BCC,   C. Infiltrative BCC
Histopathologically, micronodular BCC presents as nodular BCC, however, with 
remarkably smaller nests, also on histopathological slides the lesion is often difficult 
to demarcate. Morpheaform/infiltrative BCC is characterized by a few layers of basaloid 
cells invading collagenized stroma.(18) Basosquamous or metatypical BCC consists of a 
mix between basaloid and squamous cells and represents a collision between two skin 
neoplasms with a more aggressive growth pattern.(17, 18)
A BCC can also consist of a combination of the above mentioned subtypes within one 
lesion.(17)
If a BCC is inoperable due to its size and/or location this is considered a locally advanced 
BCC Even though BCCs are slow-growing indolent tumors, in rare cases BCC can 
metastasize. Estimates of the prevalence of metastases vary between 0.003% to 0.55%.
(19, 20) Both locally advances and metastasized BCC are referred to as advanced BCC.
(21)
Basal cell nevus syndrome
A rare genetic disorder caused by an inherited germline mutation in PTCH1 is called 
basal cell nevus syndrome (BCNS), also known as Gorlin syndrome. Patients are born 
with an already excisting PTCH1 mutation in one of the two alleles.
Alterations in both alleles of a tumour suppressor gene are required to initiate 
carcinogenesis. Since patients with Gorlin syndrome already have a germ line mutation 
in PTCH1, just one additional somatic inactivating mutation or deletion (leading to 
loss of heterozygosity, LOH) is sufficient (second hit), resulting in gene deficiency and 
initiating development to BCC. This makes BCNS patients more susceptible to develop 
BCC.(10, 11) Therefore, BCNS is characterized by the development of multiple basal cell 
carcinomas (BCCs) at a young age. Other manifestations of BCNS comprise keratocystic 
odontogenic tumours of the jaw and palmar pits.(12)
The following criteria establish the diagnosis of BCNS; (1) one major criterion and 
molecular confirmation; (2) two major criteria; or (3) one major and two minor criteria.
(13) The criteria are presented in Table 1.
Table 1. BCNS criteria according to Bree et al.
Major criteria Minor criteria
1. BCC prior to 20 years old or excessive 
numbers of BCCs out of proportion to prior 
sun exposure and skin type;
1. Rib anomalies
2. Odontogenic keratocyst of the jaw prior 
to 20 years of age;
2. Other specific skeletal malformations and 
radiologic changes (i.e., vertebral anomolies, 
kyphoscoliosis, short fourth metacarpals, 
postaxial polydactyly)
3. Palmar or plantar pitting; 3. Macrocephaly
4. Lamellar calcification of the falx cerebri; 4. Cleft/lip palate
5. Ovarian/cardiac fibroma
5. Medulloblastoma, typically desmoplastic; 6. Lymphomesenteric cysts
6. First degree relative with BCNS. 7. Ocular abnormalities
Diagnostic methods
Clinical examination seems to be very sensitive for diagnosing BCC (90%), but the 
specificity has been reported to be low (28.6-48.9%).(22, 23) Addition of dermoscopy 
can increase the specificity to 54.3%-55.6% compared to clinical examination alone.
(22, 23) With respect to discrimination between superficial and non-superficial clinical 
examination shows 89% sensitivity and a specificity of 64%.(24) Data on accuracy of 
dermoscopy in subtyping BCCs is not available.(25) Since these diagnostic methods 
are not optimal, most patients still undergo biopsy to confirm the diagnosis of BCC 
and to define the subtype. Biopsy is considered as the gold standard for diagnosis and 
subtyping of BCC.(5, 26) It is important to distinguish between the subtypes of BCC, since 
a different therapeutic approach is necessary to decrease the risk of recurrences.(5)
A biopsy is an invasive procedure and can be complicated by pain, bleeding, infection 
or scarring. Furthermore, the potential waiting period for histopathological assessment 
could be stressful for patients, but also leads to delay of treatment.
According to international guidelines, a biopsy can sometimes be omitted, but only in 
cases with a high clinical suspicion for a low risk BCC or in patients with multiple BCCs.
(26) In the last years there is a trend toward the development of more non-invasive and 
less time consuming techniques to diagnose and subtype BCCs.
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Optical coherence tomography (OCT)
OCT is a non-invasive imaging technique, producing real-time, in vivo, cross-sectional 
images of lesions with a depth of 1,5-2 mm. Although OCT is a well-established diagnostic 
tool in ophthalmology, the use of optical coherence tomography in dermatology is fairly 
new. The principle of OCT is based on light interferometry. The signal of extraction leads 
to a black and white scan, similar to an ultrasound.(27) The use of light instead of sound 
results in a higher resolution than ultrasonography.(28)
OCT provides a field of view of 6mmx6mm and a depth up to 2mm. This makes it possible 
to get a horizontal view of the different skin layers and adnexa. These horizontal images 
allow to assess the lesion and skin layers in the same direction as a histopathological 
section, making it easier to interpret for clinicians/dermatologists who are already used 
to histopathological assessment.
The machine contains a probe, which is placed on the skin lesion and within 30 seconds 
an image is made (Fig. 3.)
Figure 3. Vivosight OCT
Various histopathological structures are known to be characteristic for BCC and BCC 
subtypes.(16) These characteristics can also be recognized on OCT images. BCC in 
general can be recognized by the following characteristics on OCT: change or rupture of 
the dermo-epidermal junction; dark ovoid nests with or without a dark, hyporeflective 
halo and dilated dermal capillaries, directed toward the basal cell islands and signal free 
lateral edges (Fig. 4).(29)
Superficial BCC becomes visible on OCT in black and white nest structures originating 
from the epidermis or dermo-epidermal junction.(29, 30)
Nodular BCC on OCT shows basal cell nests localized in the papillary or superficial 
reticular dermis with no attachment to the epidermis. Around the nests a hypo 
reflective border is visible followed by a darker halo representing peripheral palisading. 
Sometimes, dilated vascular structures are seen.(29, 30)
The typical appearance of micronodules are also visible on OCT image in micronodular 
BCC.(30)
Figure 4. Images made with OCT (Maastricht UMC+, Dermatology deparment).
A. Normal skin. B. Basal cell carcinomwa with visible ovoid nests+, ruptured dermo-epidermal 
junction*.
Previous studies have shown that this OCT allows discrimination of BCC from non-BCC. 
(22, 23, 31-35) The method also has the ability to distinguish between superficial BCC 
and other subtypes in patients with clinical suspicion of superficial BCC.(31) Based on 
these studies, it seems a promising method for non-invasive diagnosis of BCC with the 
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used in the management of basal cell carcinomas such as evaluating therapy progress, 
as well as in the pre-surgical assessment of tumour resection margins.(29, 31)
If OCT appears to be a valuable diagnostic technique, this might lead to a reduction 
of the number of biopsies in the future. Before wide scale implementation of OCT 
in clinical practice, it is important to evaluate the accuracy and applicability of this 
technique when compared with standard care.
Treatment
Several different treatment options are available for BCC depending on subtype, 
localisation and whether it is a primary or secondary BCC.(3, 36-38) Age and cosmetic 
results are taken into account when discussing therapeutic options with the patients. 
Overall, costs of a treatment can also be an important determinant in the choice for 
a treatment, as insurance companies may steer in the choice between otherwise 
comparable treaments. A positive development nowadays is the increased involvement 
of patients in the process of choosing a treatment. Discrete choice experiments are 
performed to evaluate which aspects of a treatment determines the preferences of 
patients.(39, 40) Patients become more informed about their treatment in advance by 
clinicians and online information tools, making them more capable to make their own 
treatment decision. (41) The treatment of BCC is a good example in this process because 
of the multiple treatment options.
Surgical excision is still the gold standard for the treatment of BCC regardless of 
the subtype.(42-44) Approximately 30% of BCC patients will develop one or more 
subsequent BCCs, which leads to multiple excisions.(45)
Due to possible adverse events, such as infection and scarring and the fact that 
BCC usually shows a fairly benign growth pattern, non-invasive treatments become 
increasingly interesting as alternative treatment for excision, especially in patients with 
frequent excisions and consequently multiple scars.
For superficial BCCs non-invasive treatments, such as topical imiquimod 5% cream, 
5– fluorouracil (5-FU) or photodynamic therapy (PDT) are already commonly used.
(26) A large randomized controlled trial that compared these three treatments in the 
treatment of superficial BCC found that 5 years after treatment imiquimod 5% cream 
was associated with a significant lower risk of recurrence compared to 5-fluorouracil 
and PDT.(46) With a 5-year clearance rate of 82.5%, imiquimod 5% cream is therefore 
considered as the most effective non-invasive treatment. The cure rate of surgery for 
low risk BCCs is 96%-97.7% after 5 years follow-up.(5, 47) Surgery is therefore still the 
gold standard regarding efficacy, however, guidelines state that imiquimod 5% cream 
is a good alternative in patients with sBCC who prefer the benefits of non-invasive 
treatment over efficacy.(5)
For nodular BCCs, surgical excision is still considered as the first treatment option in 
(inter)-national guidelines.(26) Since nodular BCC is a low risk BCC with a compact, not 
deeply infiltrating growth, non-invasive treatment with imiquimod 5% cream was also 
expected to be a good treatment option for this indication. It has the advantage of less 
scarring and could provide a tool to treat more patients on a short notice, because 
treatment can take place directly and performed by the patients themselves. Williams 
et al compared treatment with imiquimod 5% cream to treatment with surgical excision 
for nodular BCC and found an a succes rate of imiquimod 5% cream of 81.1%, which 
was inferior to excision with a success rate of 98.8% after 5 years of follow-up.(47) 
Combining treatments might improve efficacy of imiquimod 5% cream. For example, 
the efficacy and penetration of imiquimod 5% cream treatment for nodular BCC might 
be increased by prior debulking of the tumour with curettage. Possibly, cure rates 
can be obtained comparable to those of non-invasive treatment of superficial BCC. 
Several small studies have investigated the treatment of imiquimod 5% cream with prior 
curettage and found high sustained clearance rates (90-100%)with different follow-up 
periods from 6 weeks to 1 year. However randomized controlled trials with head to 
head comparison of imiquimod 5% cream and curettage to excision are lacking.(48-51)
Most non-invasive treatments for BCC are topically applied and prescribed very often. 
However, in advanced BCC, where surgery and radiotherapy are not possible anymore, 
the only alternative is systemic treatment with a smoothened inhibitor, which specifically 
targets the hedgehog pathway. Available are the substances vismodegib and sonidegib, 
of which vismodegib is the only one that is FDA )Food and Drug Administration) and 
EMA (European Medicines Agency) approved for the treatment of advanced BCC.(52) 
Treatment with systemic hedgehog inhibitors could also be an option for patients 
with syndromal development of multiple BCCs, basal cell nevus syndrome. Due to 
the development of these multiple BCCs, surgical excision can become an unwanted 
treatment due to the excessive scarring.
This thesis focusses on surgical excision and non-invasive treatment with curettage/
imiquimod 5% cream and vismodegib. Therefore, a more detailed description of these 
treatment options for BCC is given.
Excision
For superficial and nodular BCC a 3mm clinical excision margin is accepted in the 
Netherlands, whereas for aggressive subtypes a 5mm clinical safety margin is required.
(26) Surgical excision is generally performed under local anaesthesia in a hospital 
setting. Clearance rates after 5 year follow up are 87.9% for high risk BCC and up to 
98% for low risk BCC.(47, 53) An advantage of excision is that it enables confirmation 
of tumour clearance by histopathological examination.
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Curettage
A curette is a round shaped scraper, that only shaves away superficial skin. Curettage is 
the procedure in which the curette is used to scrape away lesions, usually until the level 
of normal dermis. There is only an erosion visible which usually heals within 1 week.
According to the British guidelines for treatment of BCC, curettage and electrodessication 
(C&E) is a good treatment option for low-risk nBCCs.(42) It is a quick, relatively painless 
procedure and does not require extra hospital visits for dressing changes or suture 
removal.
However, reported recurrence rates for BCCs treated with C&E range from 7.7% to 
47%. More importantly, treatment with C&E often leads to a poor cosmetic result with 
hypertrophic scarring.(54, 55) The risk of hypertrophic scarring is generally attributed 
to the electrodessication component(56). Although curettage alone is not an accepted 
treatment modality for nBCC, in combination with a different therapy it could be an 
option.(57)
Imiquimod 5% cream
Imiquimod 5% cream is an immune-response modifier. It functions as an agonist of 
Toll-like receptor-(TLR)-7 and TLR-8. Due to activation of TLR7 and 8, a cascade of 
cytokines and chemokines is released followed by induction of an innate and cellular 
immune response against the tumour cells.(58, 59) Furthermore, imiquimod 5% cream 
has been reported to induce apoptosis on tumour cells.(60) A study on cell cultures 
suggests that imiquimod 5% cream might be able to directly inhibit sonic hedgehog 
signalling by negatively modulating GLI activity, however, evidence is still scarce .(61)
Imiquimod 5% cream is approved by the FDA and EMA for the treatment of condylomata 
acuminata, actinic keratotis and superficial BCC. In superficial BCC, imiquimod 5% cream 
is applied for 6 weeks, 5 days in a row once daily. Application should last approximately 
6-10 hours, so patients are advised to apply imiquimod 5% cream in the evening and 
remove it the next morning. Side effects include erythema, crusting, erosions, oedema, 
vesicles and even flu-like symptoms.(62)
Vismodegib (systemic smoothened inhibitor)
Smoothened (SMO) is the primary target for the development of systemic smoothened-
inhibitors for the treatment of BCC. SMO inhibition prevents the downstream activation 
of GLI transcription factors, leading to suppression of downstream genes associated with 
BCC development. Vismodegib is a hedgehog pathway inhibitor that prevents activation 
of the sonic hedgehog pathway by inhibition of the smoothened (SMO) protein (Fig. 
5).(63) Vismodegib capsules are taken daily by the patients in a dosage of 150mg once 
a day. Response rates in locally advanced BCC and metastasized BCC are approximately 
42.9 %- 66.7% and 30.3%- 37.9%, respectively.(52, 64, 65) Unfortunately, the efficacy is 
lower than first expected and adverse events are a frequent cause for discontinuation 
of vismodegib.(21) Moreover, resistance against vismodigib has been demonstrated.
(21) In the majority of cases this resistance is due to SMO mutations and to a lesser 
extent also SUFU and GLI2 mutations are found.(66, 67) The use of vismodegib should 
therefore be well considered and discussed with the patient.
Figure 5. Hedgehog signalling pathway. The mechanisme of action of vismodegib by binding to SMO.
Figure reprinted with permission: Booms P, Harth M, Sader R, Ghanaati S. Vismodegib hedgehog-
signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic 
tumors in Gorlin syndrome. Ann Maxillofac Surg. 2015;5(1):14-9.
Treatment in basal cell nevus syndrome
Although most BCCs can easily be treated with excision or topical non-invasive therapy, 
treatment is often challenging because patients can develop hundreds to thousands 
of BCCs during their lives. Radiotherapy is contraindicated, since radiation enlarges 
the susceptibility of a second hit mutation thus BCC development.(68) And even 
though the FDA only approved systemic therapy with vismodegib for the indication 
laBCC or mBCC, vismodigib seems to be valuable in the treatment of BCNS patients. 
BCNS patients have been treated with vismodegib in studies, since they also develop 
laBCC and mBCC and therefore participated in clinical trials. (21, 69) Furthermore, a 
treatment indication can be present with inoperability due to the high number of BCCs 
of up to hundreds.(70, 71) However, the disadvantages of vismodegib including adverse 
events and resistance should also be accounted for during the treatment of patients 
with BCNS. Until now, no overview of literature concerning vismodegib use in BCNS 
was available. Nevertheless, such an overview is of importance to provide the correct 
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practical work-up for this group that needs life-long treatment. Combined with other 
treatment options (e.g. excision and topical therapies), vismodegib could be valuable 
in a personalized treatment strategy for patients with BCNS.
Aims and outlines of this thesis
Currently, a lot is changing in the field of diagnosis and treatment of BCC. Since BCC 
is a relatively harmless tumour, non-invasive options are being explored. This thesis 
contributes to the development and the possible further applicability of non-invasive 
tools and treatments for basal cell carcinoma and in basal cell nevus syndrome.
Non-invasive diagnosis of basal cell carcinoma: optical coherence tomography.
In Chapter 2.1 the accuracy of OCT in non-invasive diagnosis and subtyping of BCC 
compared to clinical examination was investigated in a cohort study using punch biopsy 
as the gold standard. Furthermore, it was estimated in which proportion of patients 
with clinical suspicion of BCC a biopsy could be avoided in the future by the use of OCT.
Chapter 2.2 illustrates how a learning curve can be used to estimate the number of 
cases that need to be assessed with OCT to achieve an adequate level of performance .
Non-invasive treatment in basal cell carcinoma: therapies and preferences
Chapter 3.1 presents the results of a non-inferiority randomised controlled trial 
investigating the efficacy of treatment with curettage and imiquimod 5% cream 
compared to surgical excision in patients with nodular BCC . Furthermore, the relative 
frequency of adverse events, good cosmetic outcome and patient satisfaction is 
reported.
Patient preferences were evaluated with the use of a discrete choice experiment in 
Chapter 3.2, regarding the treatment with either curettage and imiquimod 5% cream 
or surgical excision taking into account the efficacy, adverse events, cosmetic outcomes 
and waiting period.
Non-invasive treatment with vismodegib and other hedgehog inhibitors.
A review of literature of the treatment with vismodegib and other hedgehog inhibitors 
in BCNS patients and patients with high frequency (HF) BCC patients is given in Chapter 
4.1 of this thesis. The aim of this review was to provide estimates of the frequency of 
successful treatment, adverse events and development of resistance of the available 
data on hedgehog inhibitors concerning its use and to discuss and provide a specific 
work-up for these patients who need life-long treatment. These estimates serve as a 
basis for suggestions for the clinical management of BCNS- and HF-BCC patients.
In Chapter 4.2 we discussed a patient with basal cell nevus syndrome (BCNS) with 
multiple BCCs treated with vismodegib. We describe the resistance to vismodegib which 
this patient developed in small BCNS-related BCCs, which is very rare. We performed 
mutation analyses of these BCCs to clarify the cause of resistance.
1
22 23
General introduction Chapter 1
REFERENCES
1. Flohil SC, de Vries E, Neumann HA, Coebergh JW, Nijsten T. Incidence, prevalence 
and future trends of primary basal cell carcinoma in the Netherlands. Acta dermato-
venereologica. 2011;91(1):24-30.
2. Flohil SC, Seubring I, van Rossum MM, Coebergh JW, de Vries E, Nijsten T. Trends 
in Basal cell carcinoma incidence rates: a 37-year Dutch observational study. The 
Journal of investigative dermatology. 2013;133(4):913-8.
3. Dandurand M, Petit T, Martel P, Guillot B, Anaes. Management of basal cell 
carcinoma in adults Clinical practice guidelines. European journal of dermatology: 
EJD. 2006;16(4):394-401.
4. Puig S, Berrocal A. Management of high-risk and advanced basal cell carcinoma. 
Clin Transl Oncol. 2015;17(7):497-503.
5. Work G, Baum C, Bordeaux JS, Brown M, Busam KJ, Eisen DB, et al. Guidelines of 
care for the management of basal cell carcinoma. Journal of the American Academy 
of Dermatology. 2018.
6. Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman 
C, et al. The role of the human homologue of Drosophila patched in sporadic basal 
cell carcinomas. Nature genetics. 1996;14(1):78-81.
7. Reifenberger J, Wolter M, Knobbe CB, Kohler B, Schonicke A, Scharwachter C, et al. 
Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal 
cell carcinomas. The British journal of dermatology. 2005;152(1):43-51.
8. Bakshi A, Chaudhary SC, Rana M, Elmets CA, Athar M. Basal cell carcinoma 
pathogenesis and therapy involving hedgehog signaling and beyond. Molecular 
carcinogenesis. 2017;56(12):2543-57.
9. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nature reviews Cancer. 
2008;8(10):743-54.
10. Pan S, Dong Q, Sun LS, Li TJ. Mechanisms of inactivation of PTCH1 gene in nevoid 
basal cell carcinoma syndrome: modification of the two-hit hypothesis. Clin Cancer 
Res. 2010;16(2):442-50.
11. Levanat S, Gorlin RJ, Fallet S, Johnson DR, Fantasia JE, Bale AE. A two-hit model for 
developmental defects in Gorlin syndrome. Nat Genet. 1996;12(1):85-7.
12. Bresler SC, Padwa BL, Granter SR. Nevoid Basal Cell Carcinoma Syndrome (Gorlin 
Syndrome). Head Neck Pathol. 2016.
13. Bree AF, Shah MR, Group BC. Consensus statement from the first international 
colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet A. 
2011;155A(9):2091-7.
14. Arits AH, Schlangen MH, Nelemans PJ, Kelleners-Smeets NW. Trends in the incidence 
of basal cell carcinoma by histopathological subtype. Journal of the European 
Academy of Dermatology and Venereology : JEADV. 2011;25(5):565-9.
15. Kuo KY, Batra P, Cho HG, Li S, Chahal HS, Rieger KE, et al. Correlates of multiple 
basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, 
and anatomic distribution. Journal of the American Academy of Dermatology. 
2017;77(2):233-4 e2.
16. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, 
clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 
2015;88(2):167-79.
17. Rippey JJ. Why classify basal cell carcinomas? Histopathology. 1998;32(5):393-8.
18. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. 
Modern pathology : an official journal of the United States and Canadian Academy 
of Pathology, Inc. 2006;19 Suppl 2:S127-47.
19. Snow SN, Sahl W, Lo JS, Mohs FE, Warner T, Dekkinga JA, et al. Metastatic basal cell 
carcinoma. Report of five cases. Cancer. 1994;73(2):328-35.
20. Goldenberg G, Karagiannis T, Palmer JB, Lotya J, O’Neill C, Kisa R, et al. Incidence 
and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a 
large commercially insured population in the United States: A retrospective cohort 
study. Journal of the American Academy of Dermatology. 2016;75(5):957-66 e2.
21. Basset-Seguin N, Hauschild A, Kunstfeld R, Grob J, Dreno B, Mortier L, et al. 
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of 
STEVIE, an international, open-label trial. European journal of cancer (Oxford, 
England : 1990). 2017;86:334-48.
22. Ulrich M, von Braunmuehl T, Kurzen H, Dirschka T, Kellner C, Sattler E, et al. 
The sensitivity and specificity of optical coherence tomography for the assisted 
diagnosis of nonpigmented basal cell carcinoma: an observational study. The British 
journal of dermatology. 2015;173(2):428-35.
23. Markowitz O, Schwartz M, Feldman E, Bienenfeld A, Bieber AK, Ellis J, et al. 
Evaluation of Optical Coherence Tomography as a Means of Identifying Earlier Stage 
Basal Cell Carcinomas while Reducing the Use of Diagnostic Biopsy. J Clin Aesthet 
Dermatol. 2015;8(10):14-20.
24. Roozeboom MH, Kreukels H, Nelemans PJ, Mosterd K, Winnepenninckx VJ, Abdul 
Hamid MA, et al. Subtyping basal cell carcinoma by clinical diagnosis versus punch 
biopsy. Acta dermato-venereologica. 2015;95(8):996-8.
25. Reiter O, Mimouni I, Gdalevich M, Marghoob A, Levi A, Hodak E, et al. The Diagnostic 
Accuracy of Dermoscopy for Basal Cell Carcinoma: A Systematic Review and Meta-
Analysis. Journal of the American Academy of Dermatology. 2018.
26. NVDV. Dutch guideline basal cell carcinoma, modular update. 2015.
27. Que SKT. Research Techniques Made Simple: Noninvasive Imaging Technologies 




General introduction Chapter 1
28. Fujimoto JG, Pitris C, Boppart SA, Brezinski ME. Optical coherence tomography: 
an emerging technology for biomedical imaging and optical biopsy. Neoplasia. 
2000;2(1-2):9-25.
29. Hussain AA, Themstrup L, Jemec GB. Optical coherence tomography in the diagnosis 
of basal cell carcinoma. Archives of dermatological research. 2015;307(1):1-10.
30. Olmedo JM, Warschaw KE, Schmitt JM, Swanson DL. Optical coherence tomography 
for the characterization of basal cell carcinoma in vivo: A pilot study. Journal of the 
American Academy of Dermatology. 2006;55(3):408-12.
31. Cheng HM, Guitera P. Systematic review of optical coherence tomography usage 
in the diagnosis and management of basal cell carcinoma. The British journal of 
dermatology. 2015;173(6):1371-80.
32. Olsen J, Themstrup L, De Carvalho N, Mogensen M, Pellacani G, Jemec GB. 
Diagnostic accuracy of optical coherence tomography in actinic keratosis and basal 
cell carcinoma. Photodiagnosis Photodyn Ther. 2016;16:44-9.
33. Levine A, Wang K, Markowitz O. Optical Coherence Tomography in the Diagnosis 
of Skin Cancer. Dermatol Clin. 2017;35(4):465-88.
34. Mogensen M, Joergensen TM, Nurnberg BM, Morsy HA, Thomsen JB, Thrane L, et 
al. Assessment of optical coherence tomography imaging in the diagnosis of non-
melanoma skin cancer and benign lesions versus normal skin: observer-blinded 
evaluation by dermatologists and pathologists. Dermatologic surgery : official 
publication for American Society for Dermatologic Surgery [et al]. 2009;35(6):965-72.
35. Cheng HM, Lo S, Scolyer R, Meekings A, Carlos G, Guitera P. Accuracy of optical 
coherence tomography for the diagnosis of superficial basal cell carcinoma: 
a prospective, consecutive, cohort study of 168 cases. The British journal of 
dermatology. 2016;175(6):1290-300.
36. Mosterd K, Arits AH, Thissen MR, Kelleners-Smeets NW. Histology-based treatment 
of basal cell carcinoma. Acta dermato-venereologica. 2009;89(5):454-8.
37. Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJ, et al. 
Photodynamic therapy versus topical imiquimod versus topical fluorouracil 
for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, 
randomised controlled trial. The lancet oncology. 2013;14(7):647-54.
38. Smeets NW, Krekels GA, Ostertag JU, Essers BA, Dirksen CD, Nieman FH, et al. 
Surgical excision vs Mohs’ micrographic surgery for basal-cell carcinoma of the 
face: randomised controlled trial. Lancet. 2004;364(9447):1766-72.
39. Essers BAB, Arits AH, Hendriks MR, Mosterd K, Kelleners-Smeets NW. Patient 
preferences for the attributes of a noninvasive treatment for superficial basal cell 
carcinoma: a discrete choice experiment. The British journal of dermatology. 2017.
40. Tinelli M, Ozolins M, Bath-Hextall F, Williams HC. What determines patient 
preferences for treating low risk basal cell carcinoma when comparing surgery 
vs imiquimod? A discrete choice experiment survey from the SINS trial. BMC 
dermatology. 2012;12(19).
41. van Egmond S, Wakkee M, Droger M, Bastiaens MT, van Rengen A, de Roos KP, et 
al. Needs and preferences of patients regarding basal cell carcinoma and cutaneous 
squamous cell carcinoma care: a qualitative focus group study. The British journal 
of dermatology. 2019;180(1):122-9.
42. Telfer NR, Colver GB, Morton CA, British Association of D. Guidelines for the 
management of basal cell carcinoma. The British journal of dermatology. 
2008;159(1):35-48.
43. Trakatelli M, Morton C, Nagore E, Ulrich C, del Marmol V, Peris K, et al. Update of 
the Guideline on Basal Cell Carcinoma. 2012.
44. European Dermatology Forum. Update of the Guideline on Basal Cell Carcinoma. 
2012:48.
45. Flohil SC, Koljenovic S, de Haas ER, Overbeek LI, de Vries E, Nijsten T. Cumulative 
risks and rates of subsequent basal cell carcinomas in the Netherlands. The British 
journal of dermatology. 2011;165(4):874-81.
46. Jansen MHE, Mosterd K, Arits A, Roozeboom MH, Sommer A, Essers BAB, et al. 
Five-year results of a randomized controlled trial comparing effectiveness of 
photodynamic therapy, topical imiquimod and topical 5-fluorouracil in patients 
with superficial basal cell carcinoma. The Journal of investigative dermatology. 
2017.
47. Williams HC, Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, et al. 
Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 
5-Year Results of the SINS Randomized Controlled Trial. The Journal of investigative 
dermatology. 2017;137(3):614-9.
48. Wu JK, Oh C, Strutton G, Siller G. An open-label, pilot study examining the efficacy 
of curettage followed by imiquimod 5% cream for the treatment of primary nodular 
basal cell carcinoma. The Australasian journal of dermatology. 2006;47(1):46-8.
49. Neville JA, Williford PM, Jorizzo JL. Pilot study using topical imiquimod 5% cream in 
the treatment of nodular basal cell carcinoma after initial treatment with curettage. 
Journal of drugs in dermatology : JDD. 2007;6(9):910-4.
50. Rigel DS, Torres AM, Ely H. Imiquimod 5% cream following curettage without 
electrodesiccation for basal cell carcinoma: preliminary report. Journal of drugs in 
dermatology : JDD. 2008;7(1 Suppl 1):s15-6.
51. Tillman DK, Jr., Carroll MT. A 36-month clinical experience of the effectiveness of 
curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. Journal 
of drugs in dermatology : JDD. 2008;7(1 Suppl 1):s7-14.
52. Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, et al. U.S. Food and Drug 
Administration approval: vismodegib for recurrent, locally advanced, or metastatic 
1
26 27
General introduction Chapter 1
basal cell carcinoma. Clinical cancer research : an official journal of the American 
Association for Cancer Research. 2013;19(9):2289-93.
53. Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, et al. 
Surgical excision versus Mohs’ micrographic surgery for primary and recurrent 
basal-cell carcinoma of the face: a prospective randomised controlled trial with 
5-years’ follow-up. The lancet oncology. 2008;9(12):1149-56.
54. Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of 
treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. The Journal of 
dermatologic surgery and oncology. 1991;17(9):720-6.
55. Berman B. Scientific rationale: combining imiquimod and surgical treatments for 
basal cell carcinomas. Journal of drugs in dermatology : JDD. 2008;7(1 Suppl 1):s3-6.
56. Wu JK, Oh C, Strutton G, Siller G. An open-label, pilot study examining the efficacy 
of curettage followed by imiquimod 5% cream for the treatment of primary nodular 
basal cell carcinoma. Australasian Journal of Dermatology. 2006;47(1):46-8.
57. McDaniel WE. Therapy for basal cell epitheliomas by curettage only. Further study. 
Archives of dermatology. 1983;119(11):901-3.
58. Schon MP, Schon M. Imiquimod: mode of action. The British journal of dermatology. 
2007;157 Suppl 2:8-13.
59. Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W. The use of 
Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. 
The British journal of dermatology. 2003;149 Suppl 66:53-6.
60. Huang SW, Liu KT, Chang CC, Chen YJ, Wu CY, Tsai JJ, et al. Imiquimod simultaneously 
induces autophagy and apoptosis in human basal cell carcinoma cells. The British 
journal of dermatology. 2010;163(2):310-20.
61. Wolff F, Loipetzberger A, Gruber W, Esterbauer H, Aberger F, Frischauf AM. 
Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/
protein kinase A-mediated GLI phosphorylation. Oncogene. 2013;32(50):5574-81.
62. EMA Europe imiquimod product characteristics. https://www.ema.europa.eu/
documents/product-information/aldara-epar-product-information_en.pdf
63. Erdem GU, Sendur MA, Ozdemir NY, Yazici O, Zengin N. A comprehensive review 
of the role of the hedgehog pathway and vismodegib in the management of basal 
cell carcinoma. Curr Med Res Opin. 2015;31(4):743-56.
64. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and 
safety of vismodegib in advanced basal-cell carcinoma. The New England journal 
of medicine. 2012;366(23):2171-9.
65. Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dreno B, Mortier L, et al. 
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned 
interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729-36.
66. Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, et al. 
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer 
Cell. 2015;27(3):327-41.
67. Brinkhuizen T, Reinders MG, van Geel M, Hendriksen AJ, Paulussen AD, 
Winnepenninckx VJ, et al. Acquired resistance to the Hedgehog pathway inhibitor 
vismodegib due to smoothened mutations in treatment of locally advanced basal cell 
carcinoma. Journal of the American Academy of Dermatology. 2014;71(5):1005-8.
68. Li C, Athar M. Ionizing Radiation Exposure and Basal Cell Carcinoma Pathogenesis. 
Radiat Res. 2016;185(3):217-28.
69. Chang AL, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, et al. Safety and 
efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled 
analysis of two trials. Orphanet J Rare Dis. 2016;11(1):120.
70. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. 
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. 
The New England journal of medicine. 2012;366(23):2180-8.
71. Tang JY, Ally MS, Chanana AM, Mackay-Wiggan JM, Aszterbaum M, Lindgren JA, et 
al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: 
final results from the multicentre, randomised, double-blind, placebo-controlled, 
phase 2 trial. The lancet oncology. 2016;17(12):1720-31.
1
CHAPTER 2
Non-invasive diagnosis of basal cell 
carcinoma: Optical coherence tomography
CHAPTER 2.1
Optical Coherence Tomography for 
Noninvasive Diagnosis and Subtyping of Basal 
Cell Carcinoma: A Prospective Cohort Study
Kelly A.E.Sinx*, Eva van Loo*, Erwin H.J.Tonk, Nicole W.J.Kelleners-Smeets, 
Veronique J.L.Winnepenninckx, Patty J.Nelemans^, Klara Mosterd^. 
*These authors contributed equally to this work. 
^The last two authors share senior authorship.
J Invest Dermatol. 2020 Mar 6. pii: S0022-202X(20)30242-6. 
32 33
Chapter 2.1 OCT in BCC diagnosis
ABSTRACT
Noninvasive diagnostic strategies such as optical coherence tomography (OCT) enable 
detailed examination of skin tissue architecture and have potential for identification 
and subtyping of basal cell carcinoma (BCC). To evaluate the additional diagnostic value 
of OCT, a prospective cohort study was performed in 182 patients with 250 lesions 
suspected for non-melanoma skin premalignancies requiring a biopsy. Accuracy of BCC 
diagnosis and subtype on the basis of clinical examination (CE) of patients was compared 
with that on the basis of OCT scans in conjunction with clinical images of lesions (cOCT). 
Confidence levels were recorded on a 5-point scale, where score 0 indicated absence 
of BCC and scores 1–4 indicated increasing suspicion of BCC. Diagnostic performance 
parameters were compared using histopathologic diagnosis as gold standard. The 
patient-based area under the receiver operating characteristic curve (AUC) increased 
from 85.6% for CE to 91.2% for cOCT (P = 0.061) and the lesion-based AUC from 82.7% to 
91.3% (P < 0.001). When confidence scores 1–4 were defined as positive, patient-based 
specificity increased from 47.5% (CE alone) to 76.8% (cOCT) at similar sensitivity (97.6% 
and 95.2%, respectively). cOCT slightly improved the ability to discriminate between 
superficial and nonsuperficial BCC subtypes and seemed to be a valuable addition to 
CE alone in the diagnosis and subtyping of BCC.
INTRODUCTION
Skin cancer incidence is rising worldwide. The most common type of skin cancer is 
basal cell carcinoma (BCC). The general population has a lifetime risk of 16–20% to 
develop a BCC (Flohil et al., 2011). A punch biopsy is required to discriminate BCC from 
alternative diagnoses and to determine the histopathologic subtype (NVDV, 2015, Work 
Group et al., 2018). Knowledge of the histopathologic subtype is especially relevant 
in determining the optimal treatment. In case of superficial BCC, treatment with a 
topical therapy may be prescribed. In nonsuperficial BCCs, information of the subtype 
helps to determine the width of resection margins or to set an indication for Mohs’ 
micrographic surgery. A punch biopsy is an invasive procedure that may be painful and 
carries a small risk of complications such as bleeding, scarring, and infection. Moreover, 
awaiting histologic assessment (approximately 1 week) causes treatment delay and 
can be stressful for patients. With the high volume of BCCs and potential drawbacks of 
invasive diagnostics, interest in noninvasive diagnostic methods is increasing. Optical 
coherence tomography (OCT) is an imaging technique that generates real-time in vivo 
cross-section images of tissue microarchitecture with a depth of 1.5–2 mm (Cheng and 
Guitera, 2015). OCT is based on light interferometry; the interference of two optical 
beams reflected by the tissue produces distinguishable shades in the black and white 
spectrum. Morphologic characteristics of BCC that may be distinguished on OCT images 
have been established in recent years (Hussain et al., 2015). Small studies coordinated 
by the OCT producers with selected patient populations have reported promising results 
with the use of OCT in diagnosing BCC and subtyping of superficial BCC (Cheng et al., 
2016, Markowitz et al., 2015, Ulrich et al., 2015). A recent Cochrane Diagnostic Test 
Accuracy review on the accuracy of OCT for diagnosis of BCC stated that the small 
number of studies and varying methodologic quality make it impossible to guide 
practice (Ferrante di Ruffano et al., 2018). This prospective cohort study was initiated to 
investigate the ability of OCT in conjunction with clinical images (cOCT) to discriminate 
between (i) BCC and other diagnoses and (ii) superficial and nonsuperficial (nodular and 
aggressive) subtypes of BCC. An additional objective was to evaluate how often OCT 
scans, in conjunction with clinical images of lesions (cOCT) imaging, enabled making a 
diagnosis of BCC with high confidence and how many lesions would be misclassified if 
the punch biopsy would have been omitted in these cases.
METHODS AND MATERIALS
A prospective cohort study was conducted at the Dermatology outpatient clinic of 
the Maastricht University Medical Center, Maastricht, The Netherlands. Adult patients 
(18 years or older) receiving a skin biopsy of a lesion clinically suspected for a non-
melanoma skin cancer or premalignancy were included in this study. Patients who were 
incompetent to sign informed consent were excluded.
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CE consisted of macroscopic and/or visual examination and dermoscopic evaluation 
(Heine Delta 20T) by the treating physicians. The level of confidence in the diagnosis was 
documented using a 5-point Likert-scale ranging from 0 to 4 by the treating physician 
(Figure 1). If there was any suspicion of BCC on the basis of clinical characteristics (such as 
shiny border, telangiectasia, ulceration) and dermoscopic findings (such as telangiectasia 
or ovoid nests), the most likely BCC subtype (superficial, nodular, or aggressive) was 
recorded by the physician. The physician marked the biopsy area of the clinically most 
aggressive part and a photograph was taken by a medical photographer (Nikon D750). 
A dermoscopic image was only taken if indicated by the physician. In the same patient 
consultation, the marked biopsy area was scanned with OCT without any preparations 
of the skin in advance (Vivosight Multi-beam Swept-Source Frequency Domain OCT, 
Michelson Diagnostics, Maidstone, Kent, United Kingdom; specifications: class 1 eye 
safe, resolution <7.5 μm lateral, <5 μm axial, depth of focus = 1.0 mm, scan area = 6 × 6 
mm). During the same consultation and following the OCT scan, a 3 mm punch biopsy 
was taken according to regular care. The histopathologic outcome served as the gold 
standard and was diagnosed by independent specialized dermato-pathologist with 
over 10 years of experience, blinded to the OCT images. BCC subtypes were classified 
as either superficial, nodular, or aggressive BCC. In case of mixed subtypes, the most 
aggressive subtype was used for analysis.
Figure 1. Classification of diagnosis according to level of confidence in BCC diagnosis and BCC 
subtype. BCC, basal cell carcinoma; DD, differential diagnosis.
OCT images were coded and saved anonymously. These OCT images in conjunction 
with clinical photographs (cOCT) were assessed by two researchers who had received 
training and had previous experience with OCT. Diagnosis was based on the criteria for 
OCT assessment, as previously described (Hussain et al., 2015). The two researchers 
documented the level of confidence in the ultimate diagnosis that was reached by 
consensus using the 5-point Likert-scale. When BCC was suspected, BCC subtype was 
also recorded (Figure 1). The assessors were blinded for the results of histopathologic 
examination. This study was approved by the local independent Ethics Committee. All 
patients provided written informed consent.
Statistical analysis
This study was based on data from 182 patients with a total of 250 lesions. The data 
were part of a dataset of 400 lesions in 289 consecutive patients between February 
2017 and May 2017. The first 150 lesions were used for training purposes. Before this 
study, it was assumed that the prevalence of BCC in our study population of patients 
suspected for non-melanoma skin cancer or premalignancy was about 45% (on the 
basis of retrospective unpublished data of our department). The goal was to evaluate 
whether the use of cOCT will result in an increase of specificity when compared with 
CE alone at similar sensitivity. On the basis of the literature, sensitivity and specificity 
of CE were estimated at 95% and 45%, respectively (Markowitz et al., 2015, Ulrich et al., 
2015). Thus, 100 patients without BCC (55% of 182) were expected to be available for 
evaluation of specificity. This number enabled detection of an increase of specificity by 
20% or more (from 45% to 65%) with a power of 80% (two-sided alpha = 5%).
The primary analysis was performed on the level of patients, where only one lesion per 
patient was included to ensure independence of observations. A secondary analysis 
was performed on the level of lesions. The diagnostic performance of CE alone and 
OCT images in cOCT was expressed by sensitivity, specificity, positive predictive value, 
negative predictive value, and AUC with corresponding 95% confidence intervals.
Receiver operating characteristic curves were constructed, where each point on the 
receiver operating characteristic curve represented a sensitivity and specificity pair 
corresponding to different thresholds for a positive test result. Receiver operating 
characteristic curves visualized the trade-off between sensitivity and specificity and 
the AUC was used as a measure of global diagnostic performance (Obuchowski, 2003).
With respect to the ability of cOCT to distinguish between BCC subtypes, we focused 
on the ability to discriminate between superficial BCC and nodular and/or aggressive 
BCC. This distinction was relevant to decide whether excision was required or not. For 
BCC subtyping, sensitivity was defined as the proportion of patients with histologically 
verified nonsuperficial BCC (requiring excision) that were detected. Specificity was 
defined as the proportion of patients with histologically verified superficial BCC (not 
requiring excision) that were identified as superficial BCC.
Differences in diagnostic performance parameters between CE alone and cOCT were 
tested for statistical significance using the McNemar test for paired proportions. For 
the paired comparison between the AUC of CE and cOCT, an algorithm developed by 
DeLong et al. was used (DeLong et al., 1988).
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SPSS (version 23) and STATA (version 13.1, StataCorp LLC, College Station, TX) were 
used for statistical analyses. Two-sided P-values of 5% were considered to indicate 
statistical significance.
RESULTS
A total of 182 patients with 250 lesions clinically suspicious for non-melanoma skin 
cancer or premalignancy were included in this study. All lesions were scanned by OCT 
and histopathologically verified by either punch biopsy or excision biopsy. If patients had 
multiple lesions, the first scanned lesion was selected for the analysis on patient level. 
The patient-based analysis therefore consisted of 182 lesions, of which 83 were BCCs 
and 99 were non-BCCs, corresponding to a BCC prevalence of 45.4%. Of those 83 BCCs, 
26 (31.3%) were superficial BCCs, 36 (43.4%) nodular BCCs, and 21 (25.3%) aggressive 
BCCs. Patient and lesion characteristics are summarized in Table 1.
Table 1. Baseline Characteristics of Patient and Lesion-Based Analysis; For Categorical 
Variables Percentages (Absolute Numbers) Are Given
Characteristic Patient-Based Lesion-Based
Mean age (SD) 66.8 (13.0) 67.4 (13.5)
Sex, n (%)
 Male 93 (51.1)
 Female 83 (45.6)
Localization, n (%)
 Head/neck 96 (52.7) 123 (49.2)
 Trunk 51 (18.0) 72 (28.8)
 Extremities 35 (19.2) 55 (22.0)







 BCC 83 (45.6) 116 (46.4)
 No BCC 99 (54.4) 134 (53.6)
BCC subtypes, n(%)
 Superficial BCC 26 (31.3) 34 (29.3)
 Nodular BCC 36 (43.4) 56 (48.3)
Table 1. Continued
Characteristic Patient-Based Lesion-Based
 Aggressive BCC 21 (25.3) 26 (22.4)
Other diagnoses (non-BCC), n(%)
Benign1 48 (48.4) 62 (46.3)
SCC 19 (19.2) 23 (17.2)
Actinic keratosis 17 (17.2) 24 (17.9)
Bowen’s disease 13 (13.1) 23 (17.2)
Atypical fibroxanthoma 1 (1.0) 1 (0.7)
CD30 proliferation 1 (1.0) 1 (0.7)
Abbreviations: BCC, basal cell carcinoma; SCC, squamous cell carcinoma.
1 Including: sebaceous gland hyperplasia and/or adenoma, dermatofibroma, folliculitis, dermal 
nevus, seborrhoic keratosis, scar, pseudolymphoma, interfase dermatitis, benign lichoid keratosis.
Ability to distinguish basal cell carcinoma from non–basal cell carcinoma
The area under the receiver operating characteristic curve (AUC) was 85.6% (95% 
confidence interval = 80.2–89.0%) for clinical examination (CE) alone and 91.2% (95% 
confidence interval = 86.7–95.8%) for cOCT improvement in diagnostic performance 
(P = 0.061) (Figure 2).
Figure 2. ROC curves for clinical examination and cOCT. cOCT, optical coherence tomography 
in conjunction with clinical images; ROC, receiver operating characteristic.
ROC curves of both patient (a) - and lesion based (b) analysis
The trade-off between sensitivity and specificity at different thresholds (on the basis of 
level of confidence) for a positive test result are shown for CE and cOCT (Table 2). When 
confidence scores 1–4 were considered as test positives and confidence score of 0 as 
test negative, sensitivity was 97.6% for CE and 95.2% for cOCT (P = 0.687). Specificity 
increased from 47.5% for CE to 76.8% for cOCT (P < 0.001). Positive predictive values 
a          b
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were 60.9% for CE and 77.5% for cOCT, and negative predictive values were 95.9% and 
95.0%, respectively.
Table 2. Diagnostic Performance of CE and OCT in cOCT from Patient-Based (182) and Lesion-










Cutoff 1234 versus 0
Sensitivity 97.6 (90.8–99.6) 95.2 (87.5–98.4) 97.4 (92.1–99.3) 95.7 (89.7–98.4)
Specificity 47.5 (37.4–57.7) 76.8 (67.0–84.4) 43.3 (34.8–52.1) 73.1 (64.7–80.2)
PPV 60.9 (52.0–69.1) 77.5 (67.9–84.9) 59.8 (52.4–66.8) 75.5 (67.6–82.1)
NPV 95.9 (84.7–99.2) 95.0 (87.0–98.4) 95.1 (85.4–98.7) 95.1 (88.5–98.2)
Cutoff 234 versus 01
Sensitivity 81.9 (71.6–89.2) 88.0 (78.5–93.8) 82.8 (74.4–88.9) 87.9 (80.3–93.0)
Specificity 75.8 (65.9–83.6) 85.9 (77.1–91.8) 70.1 (61.5–77.6) 85.1 (77.6–90.4)
PPV 73.9 (63.5–82.3) 83.9 (74.1–90.6) 70.6 (62.1–77.9) 83.6 (75.6–89.5)
NPV 83.3 (73.7–90.1) 89.5 (81.1–94.6) 82.5 (73.9–88.7) 89.1 (82.0–93.7)
Cutoff 34 versus 012
Sensitivity 54.2 (43.0–65.1) 72.3 (61.2–81.3) 56.0(4.5–65.1) 70.7 (61.4–78.6)
Specificity 90.9 (83.0–95.5) 91.9 (84.2–96.2) 87.3 (80.1–92.2) 91.8 (85.4–95.6)
PPV 83.3 (70.2–91.6) 88.2 (77.6–94.4) 79.3 (68.6–87.1) 88.2 (79.4–93.7)
NPV 70.3 (61.5–78.0) 79.8 (71.1–86.5) 69.6 (62.0–76.4) 78.3 (70.9–84.3)
Cutoff 4 versus 0123
Sensitivity 10.8 (5.4–20.1) 59.0 (47.7–69.5) 12.1 (6.9–19.7) 58.6 (49.1–67.6)
Specificity 100 (95.3–100.0) 93.9 (86.8–97.5) 98.5 (94.2–99.7) 94.8 (89.1–97.7)
PPV 100 (62.8–100.0) 89.1 (77.1–95.5) 87.5 (60.4–97.8) 90.7 (81.1–95.8)
NPV 57.2 (49.5–64.6) 73.2 (64.5–80.5) 56.4 (49.8–62.8) 72.6 (65.2–78.9)
Abbreviations: CE, Clinical Examination; CI, confidence interval; cOCT, OCT in conjunction with clinical 
images; NPV, negative predictive value; OCT, optical coherence tomography; PPV, positive predictive value.
When only a confidence score of 4 was considered as test positive and confidence 
scores 0–3 as test negatives, higher specificity was observed for CE (100%) than for 
cOCT (93.9%) (P = 0.0313). Sensitivity of CE (10.8%) was significantly lower than that 
of cOCT (59.0%) (P < 0.001). The positive predictive values increased to 100% for CE 
and 89.1% for cOCT, whereas negative predictive value decreased to 57.2% for CE and 
73.2% for cOCT.
Ability to distinguish between subtypes of basal cell carcinoma
Accurate subtyping of BCCs is important to decide whether an excision is indicated 
(nonsuperficial BCC) or whether the BCC can be treated noninvasively (superficial BCC). 
There were 83 histologically confirmed BCCs in the database (57 nonsuperficial BCCs 
and 26 superficial BCCs).
Of the 83 histologically verified BCCs, CE detected 81 BCCs and cOCT identified 79 BCCs. 
There was overlap in 77 BCCs (54 nonsuperficial BCCs and 23 superficial BCCs), which 
were used for the paired comparison of subtyping ability of CE and cOCT (Table 3). 
Sensitivity to detect nodular and/or aggressive BCC was 87.0% for CE and 88.9% for 
cOCT (P = 1). Specificity to detect superficial BCC significantly increased from 47.8% 
with CE to 78.3% with cOCT (P = 0.031)



























































































Abbreviations: BCC; basal cell carcinoma; CI, confidence interval; CE, clinical examination; cOCT, 
OCT in conjunction with clinical images; NPV, negative predictive value; OCT, optical coherence 
tomography; PPV, positive predictive value; sBCC, superficial basal cell carcinoma.
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Sensitivity was defined as the proportion of patients with histologically verified 
nonsuperficial BCC (requiring excision) that were detected. Specificity was defined as 
the proportion of patients with histologically verified superficial BCC (not requiring 
excision) that were identified as superficial BCC.
Optical coherence tomography in conjunction with clinical images diagnosis of basal 
cell carcinoma made with high confidence (level 4)
In a clinical scenario, high confidence in the presence of BCC according to cOCT 
diagnosis could lead to a treatment decision without the need for verification of the 
histopathologic diagnosis by punch biopsy. To evaluate the outcome of this potential 
scenario, the ability to predict BCC and subtype was evaluated within the group of 
cases in which BCC was diagnosed by cOCT with a confidence score of 4. Certainty 
about presence of BCC and subtype according to cOCT was observed in 55 of 182 
patients (30%) (Table 4). According to histopathology, 49 of those 55 lesions were BCCs 
(positive predictive values = 89.1%). The other six diagnoses were one actinic keratosis, 
one sebaceous gland adenoma, one Bowen’s disease, two interface dermatitis, and one 
benign lichenoid keratosis.
Table 4. BCC Diagnosis and Subtyping by cOCT Correlated to Histopathologic Diagnosis for 
Patient-Based (55) and Lesion-Based (75) Analysis Diagnosed with High Confidence (score 4)











Superficial 3 13 2 18 3 18 7 28
Nonsuperficial 3 2 32 37 4 2 41 47
Total 6 15 34 55 7 20 48 75
Abbreviations: BCC, basal cell carcinoma; cOCT, OCT in conjunction with clinical images; OCT, 
optical coherence tomography.
According to histologic subtyping, those 49 BCCs consisted of 15 superficial BCCs and 
34 nonsuperficial BCCs. With respect to subtyping, sensitivity to detect nonsuperficial 
BCCs was 94.1% (32 of 34) for cOCT compared with 91.1% (31 of 34) for CE (P = 1). 
Specificity for cOCT was 86.7% (13 of 15) and higher than that for CE at 53.3% (8 of 15) 
(P = 0.063) (Table 3).
Table 4 shows that, in total, 18 BCCs were classified as superficial BCC by cOCT, but five 
of these lesions were misclassified. Of those, two were nonsuperficial BCC (nodular BCC) 
and three lesions turned out to be two interface dermatitis and one benign lichenoid 
keratosis. A total of 37 lesions were classified as nonsuperficial BCC by cOCT. Of those, 
32 were indeed nonsuperficial BCC. A total of two lesions were actually superficial BCC 
and three lesions turned out to be one Bowen’s disease, one actinic keratosis, and one 
sebaceous gland adenoma.
Lesion-based analysis
The 182 patients who were included in this study had a total of 250 lesions. The number 
of patients with one or more lesions are described in Table 1. The 250 lesions consisted 
of 116 BCCs and 134 non-BCCs, corresponding to a BCC prevalence of 46%. Of the 
116 BCCs, 34 (29.3%) were superficial BCCs, 56 (48.3%) nodular BCCs, and 26 (22.4%) 
aggressive BCCs. The results from lesion-based analyses are also presented, enabling 
comparison with the results from patient-based analyses. There were small differences 
in the estimates for diagnostic parameters, and a statistically significant increase from 
82.7% to 91.3% in AUC was observed (P < 0.001).
DISCUSSION
This study shows that the use of OCT in conjunction with clinical pictures demonstrates 
a better ability to differentiate BCC from other diagnoses when compared with CE alone. 
In both analyses, the AUC indicated better diagnostic performance for cOCT than for 
CE. When confidence scores 1–4 were considered as test positive (versus score 0 as 
test negative), addition of cOCT was associated with a significant increase in specificity 
from 47.5% to 76.8% without compromising sensitivity. Previous studies also found 
increase in specificity without affecting sensitivity (Cheng et al., 2016, Markowitz et al., 
2015, Ulrich et al., 2015).
This study showed that the ability of cOCT to discriminate between superficial and 
nonsuperficial BCCs (nodular BCC and aggressive BCC) was slightly better compared 
with that of CE. With cOCT, a larger proportion of histologically verified superficial 
BCC was detected than with CE, meaning higher specificity of cOCT compared with 
CE alone. Sensitivity to detect nonsuperficial BCCs (nodular BCC and aggressive BCC) 
increased only slightly. An explanation for this finding may be that sensitivity of CE 
alone is already high (87.0%). Nodular BCCs are clinically well recognizable, having 
characteristic features such as elevation, a pearly translucent margin, and telangiectasia. 
The typical shiny appearance of a nodular BCC is even better seen when a light beam 
is moved over the tumor. Owing to the design of the study, the assessors of cOCT had 
to do with photographs in which elevation and shiny appearance are obviously less 
clear. Recognition of nodular BCC might improve when cOCT is used directly during 
CE of a patient.
In this study, we performed both a patient-based and a lesion-based analyses. The 
patient-based analysis using only one lesion per patient ensures independence of 
observations and provides information on the proportion of patients who are diagnosed 
correctly. However, in the patient-based analysis, there is a risk of missing an OCT 
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diagnosis of BCC if a patient with multiple lesions has a BCC or other malignancy in a 
lesion that is not included for analysis. This occurred in one patient. The lesion-based 
analysis gives information on the proportion of lesions with a correct diagnosis and is 
also relevant because generally treatments are chosen per lesion. Treatments of BCC 
lesions are usually not systemic and the decision to treat one lesion and leave one 
untreated can be taken at once. Although there were small differences in the estimates 
of diagnostic parameters, both analyses led to similar conclusions. A significant 
difference in AUC between cOCT and CE was found in the lesion-based analysis, but 
significance was not reached in the patient-based analysis owing to a limited power.
The idea has been put forward that noninvasive diagnostic techniques, such as OCT, 
may make it possible to omit punch biopsy in part of the patients for whom the OCT 
diagnosis of BCC can be made with high confidence (Cheng et al., 2016, Markowitz 
et al., 2015). In this way, the delay caused by the necessity for a punch biopsy could be 
avoided. For this reason, this study evaluated whether the predictive value in case of 
high confidence in the cOCT diagnoses was high enough to guarantee that the prognosis 
of patients was not compromised and that over- or undertreatment could be avoided. 
In this study, high confidence (level 4) in BCC diagnosis with cOCT was observed in 30% 
(55 of 182) of patients.
Within the subgroup of 55 lesions in which BCC was diagnosed with high confidence 
by cOCT, six lesions turned out not to be BCC after histologic verification. In one case, 
Bowen’s disease was diagnosed by cOCT as nodular BCC with high certainty (score 4). If 
treatment would have been started on the basis of the cOCT diagnosis, the treatment 
would have been surgery, which is an adequate treatment for Bowen’s disease. In one 
patient with two lesions, the second lesion (not included in the patient-based analysis) 
was a histologically verified squamous cell carcinoma that was diagnosed as nodular BCC 
by cOCT. Treatment would have been surgery, but misclassification of invasive tumors 
like squamous cell carcinoma or melanoma as BCC is always undesirable.
For subtyping of BCC, two of the 55 lesions diagnosed as BCC with high confidence were 
histologically nodular BCC that were misdiagnosed as superficial BCC. Consequently, 
these lesions would have been treated with noninvasive therapy instead of surgical 
excision. Treatment of nodular BCC with imiquimod is inferior to surgical excision, but 
results of the SINS trial showed a 5-year sustained clearance of 81% and recurrences 
are detected early and can easily be retreated with excision (Williams et al., 2017). 
Unnecessary surgery could have occurred in the patients with actinic keratosis and 
sebaceous gland adenoma, both misdiagnosed as nodular BCC. The patients with 
interface dermatitis and benign lichenoid keratosis that were diagnosed as superficial 
BCC by cOCT would probably have been overtreated with noninvasive therapy. The 
risk of over- or undertreatment must be weighed against the advantage of treatment 
without diagnostic delay and less invasive procedures. More importantly, the scenario 
described above is a hypothetic scenario, and whether OCT-guided diagnosis and 
treatment compromised effectiveness in terms of remaining free from recurrences in 
the long term cannot be concluded from this diagnostic study and needs to be verified 
in a randomized trial comparing the long-term effect of an OCT-guided strategy with 
standard care.
Instead of retrospectively looking at the scans and the opportunity to obtain a second 
scan of a different area within the tumor in case of doubt of the diagnosis, a real-time 
scanning could benefit the outcome of the OCT-guided strategy. As with all diagnostic 
procedures, increased training yields better results. In this study, we excluded the first 
150 scans for training purposes. Therefore, the diagnostic performance of OCT is likely 
to improve after more training.
In conclusion, this study shows that the use of cOCT improves ability to distinguish 
between BCC and other diagnoses in patients with lesions clinically suspected for a non-
melanoma skin cancer or premalignancy. Ability to distinguish between BCC subtypes 
needs further improvement. This may be realized with more training and under optimal 
conditions using OCT directly during CE of a patient. If treatment would be guided by 
OCT diagnosis, a punch biopsy could be omitted in about 30% of patients. This strategy 
harbors a small risk of misclassifications.
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ABSTRACT
The amount of training needed to correctly interpret optical coherence tomography 
(OCT) is undefined. The objective of this study was to illustrate how cumulative sum 
(CUSUM) charts can be used in determining how many OCT scans novice assessors 
should evaluate in order to obtain competence in diagnosing basal cell carcinoma. 
Four hundred lesions suspect for non-melanoma skin cancer were evaluated by OCT 
in combination with clinical photographs, using a five-point confidence scale. The 
diagnostic error rate (sum of false negative and false positive OCT results / total number 
of cases) was used to evaluate performance, with histopathologic diagnosis as the 
reference standard. Acceptable and unacceptable error rates were set at 16% and 
25%, respectively. Adequate performance was reached after assessing 183-311 scans, 
dependent on the cut-off for a positive test result. In conclusion, CUSUM analysis is 
useful to monitor progress of OCT trainees. The caseload necessary for training seems 
substantial.
ABBREVIATIONS
OCT: optical coherence tomography; BCC: basal cell carcinoma; CUSUM: cumulative 
sum; NMSC: non-melanoma skin cancer
INTRODUCTION
The incidence of non-melanoma skin cancer (NMSC) has risen over the past decades 
with basal cell carcinoma (BCC) being the most prevalent cancer in the Caucasian 
population worldwide.(1-3) BCC diagnosis is often confirmed histopathologically by 
a biopsy, which also allows BCC subtyping and accommodates choosing the most 
appropriate treatment.(4) Biopsies are invasive, may be painful and can be complicated 
by for example bleeding.(5) Moreover, histological assessment takes time and treatment 
may only be started following a second consultation. In the last years, non-invasive 
diagnostic techniques have improved and interest in its application for skin cancer is 
comprehensively growing. Optical coherence tomography (OCT) was first described 
as a potential imaging method for dermatology in 1997.(6) It relies on the reflection 
of light to obtain cross-sectional images of tissue, with an axial resolution of about 15 
microns and a detection depth of around 1.5 mm.(7) Real time, in vivo images of tissue 
microarchitecture are provided. For BCC, morphological features on OCT have been 
defined which show high concordance with regular histopathology slides.(8-11) Several 
studies explored the diagnostic value of OCT for discrimination between BCC and other 
diagnoses and reported high sensitivity (≥ 80%) with specificity ranging from 75 to 96%.
(12-15) Higher diagnostic accuracy has been described for more experienced observers.
(12, 16) However, data on learning curves for OCT interpretation is not available, whilst 
this is valuable information for physicians who consider working with OCT. We studied 
the learning curve for OCT-assisted diagnosis of BCC using cumulative sum (CUSUM) 
analysis. Our aim was to illustrate how CUSUM charts can be used to determine how 
many OCT scans have to be evaluated by novice assessors to achieve an adequate level 
of competence in distinguishing BCC from other diagnoses.
MATERIAL AND METHODS
The research database of a prospective observational cohort study, initiated at the 
outpatient clinic of the Dermatology department of the Maastricht University Medical 
Centre+ (MUMC+), Maastricht, the Netherlands, was used.(17) The study was approved 
by the Medical Ethical Committee of MUMC+.
Patients, 18 years or older, receiving a skin biopsy of a lesion clinically suspect for 
a NMSC or pre-malignancy were included between February 15 and June 29, 2017. 
Written informed consent was obtained. Excluded were patients incompetent to sign 
informed consent. The physician marked the area for biopsy and clinical and (if ordered 
by the physician) dermoscopic pictures were taken by a medical photographer. The 
marked biopsy area was scanned with OCT (VivoSight OCT, Michelson Diagnostics) 
and consecutively a 3-mm punch biopsy was taken. Histopathology was assessed by 
independent pathologists, unaware of the OCT diagnosis.
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OCT images were coded and saved anonymously. OCT assessment was performed by 
two researchers who evaluated the clinical (and if available, dermoscopic) pictures in 
conjunction with the OCT images. Assessment of the OCT images on presence of BCC 
was based on the criteria described by Hussain et al. and the VivoSight online atlas 
(Table 1).(8, 18) Level of confidence in the diagnosis of BCC was documented using a 
5-point Likert-scale (range: 0-4, Table 2).
Table 1: Criteria used for assessing optical coherence images on presence and subtyping of 
basal cell carcinoma*
Presence of basal cell carcinoma
 Disruption of layering
 Hyporeflective ovoid structures
 Dark areas surrounded by a hyperreflective halo
 Peritumoural white/ refractile stroma
 Palisading at margin
 Necrosis
 Widened epidermis
*Adapted from Hussain et al. and vivosightatlas.com
The OCT assessors reached consensus on each OCT scan and were unaware of 
histopathological results before making a final diagnosis. In order to accommodate 
the learning process, the assessors received immediate feedback of histopathologic 
outcome after each scan for the first 100 scans. For the remaining cases in the database, 
feedback on histopathologic outcome was given after every 10-15 scans.
Table 2: Level of confidence in diagnosis of BCC on OCT and definition of positive and negative 
OCT test results according to two different cut-off values of the confidence score
Cut-off value of confidence score for a positive test result
Level of confidence Cut-off ≥ 2 Cut-off ≥ 3
0: certainly no BCC No BCC (negative test result) No BCC (negative test result)
1: low suspicion of BCC No BCC (negative test result) No BCC (negative test result)
2: high suspicion of BCC, other 
diagnosis may be possible
BCC (positive test result) No BCC (negative test result)
3: certain of BCC diagnosis, 
unsure of subtype
BCC (positive test result) BCC (positive test result)
4: certain of BCC diagnosis and 
subtype
BCC (positive test result) BCC (positive test result)
OCT= optical coherence tomography, BCC= basal cell carcinoma
The diagnostic error rate, defined as the sum of false negative and false positive OCT 
results as a proportion of the total number of cases, was used as the criterion to assess 
diagnostic performance in this study, with histopathological diagnosis as reference 
standard.
Training prior to the study
Before the start of the study, the OCT assessors received instructions on BCC diagnosing 
and subtyping with OCT by a representative of the manufacturer. Also literature on OCT 
in dermatology was studied and an OCT convention was attended.(19) Around 20 OCT 
scans were assessed purely for educational purposes and to get familiar with the OCT 
device (scans not included in this study).
One of the OCT assessors had several years of clinical experience with diagnosis and 
treatment of BCC (including mohs surgery) as a dermatology resident, and one had two 
years of experience in clinical dermato-oncology as a research fellow.
Learning curve analysis
A cumulative sum (CUSUM) chart was used to track performance over time and was 
constructed using an Excel spread sheet.(20) CUSUM is an analysis technique typically 
used for sequential monitoring of cumulative performance and detection of change in 
performance over time. CUSUM charts were originally developed for industrial process 
monitoring and are based on the classification of a product’s quality into one of two 
categories: ‘defective’ or ‘non-defective’.(21) The purpose is to detect changes in the 
proportion (p) of items in the ‘defective’ category. It is necessary to pre-specify an 
acceptable failure rate (p0) and an unacceptable failure rate (p1). In the same manner, a 
CUSUM chart can be applied to evaluate the learning process in medical interventional 
and diagnostic techniques.(20, 22-25) The outcome of the diagnostic technique (in this 
case OCT) has to be classified into ‘success’ or ‘failure’. For construction of the CUSUM 
chart, the cumulative sum after each case is plotted against the index number of that 
case. For each failure, a certain score ( , see formula in Appendix 1) is added and for 
each success, a score ( ) is subtracted. The CUSUM is the running sum of a mixture 
of increments (with each failure) and decrements (with each success). A continuing 
descending curve indicates that successes occur more frequently than failures.
When the running sum exceeds a certain threshold boundary, this signals a critical 
change. The upper and lower limits represent the boundary above which performance 
becomes unacceptable (h0) or below which performance becomes acceptable (h1), 
respectively. These boundaries depend on the setting of p0 and p1, but also on the 
setting of the false positive or type I error (α, risk of falsely concluding that a trainee’s 
performance is unacceptable when it is not) and the false-negative or type II error (β, 
the risk of falsely concluding that a trainee’s performance is acceptable when it is not). 
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The type I and type II error are conventionally set at 0.1, making h0 and h1 equal.(22) 
For a detailed explanation see Appendix 1.
The primary endpoint in this study was the number of OCT assessments after which an 
adequate level of competence was achieved. A cut-off value of the confidence score in 
the OCT diagnosis has to be chosen to define positive and negative test results. CUSUM 
curves were made using two alternative cut-off values; ≥2 and ≥3 on the Likert scale 
(Table 2). All diagnoses were compared with the histopathological diagnosis.
The acceptable diagnostic error rate was set at 16% and the unacceptable error rate 
at 25%.
RESULTS
400 OCT scans with corresponding clinical images of 400 lesions in 289 patients were 
included. All lesions were clinically suspicious for NMSC or pre-malignancy. Of all 289 
patients, 208 had one lesion, 63 had two, ten had three, six had four and two had six 
lesions. Lesion characteristics are presented in Table 3. Histopathology results revealed 
a total of 192 BCCs and 208 other diagnoses.
Table 3: Characteristics of the 400 lesions included in the study
N=400 %
Location




Basal cell carcinoma 192 48.0
Actinic keratosis 42 10.5
Morbus Bowen 24 6.0
Squamous cell carcinoma 29 7.3
 Melanoma or lentigo maligna 2 0.5
 Other malignant 6 1.5
Benign naevoid 13 3.3
Other benign tumours 34 8.5
Inflammatory 36 9.0
Inconclusive diagnosis 6 1.5
Other 16 4.0
When using a cut-off value ≥ 2, high suspicion of BCC (score 2) as well as certainty of 
the presence of BCC (scores 3 and 4) are defined as a test-positive result of OCT. There 
were 23 false negative diagnoses and 40 false positive diagnoses corresponding with an 
overall error rate of 15.8% (63/400). The CUSUM curve is presented in Figure 1. From 
case 55 onwards the curve starts declining, and definitively crosses the acceptable 
boundary (h1) from above at case number 183. This crossing signals that the hypothesis, 
that acceptable performance at the pre-set error rate of 16% has been reached, can 
be accepted (with α=0.1 and β=0.1). The CUSUM curve keeps declining indicating that 
performance remains acceptable.
Figure 1: Cumulative sum (CUSUM) curve for optical coherence tomography (OCT) assisted 
diagnosis of basal cell carcinoma (n=400), with p0 = 16% and p1 = 25% for cut-off value level 
of confidence ≥2 and ≥3.
When using a cut-off value ≥ 3, only certainty of BCC presence on OCT is defined as a 
positive test result. There were 48 false negative and 26 false positive OCT diagnoses 
corresponding with an overall error rate of 18.5% (74/400). The curve initially courses 
around and above the x-axis, indicating a ‘trial and error’ state until case 52 (Figure 1). 
It first crosses the acceptable boundary (h1) from above at case 202, but subsequently 
fluctuates around the critical h-line giving it an overall horizontal course to definitely 
cross it from above at case 311. At this point, the hypothesis that the diagnostic error 
rate reached 16%, can be accepted.
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DISCUSSION
With this study we illustrated how the CUSUM method can be used to create learning 
curves and estimate after how many OCT scans diagnostic performance meets pre-
specified standards.
Learning curves graphically show the relationship between learning effort and 
achievement. The benefit of CUSUM is that it continuously assesses individual 
performance and progress in mastering a new technique.(20) It also serves as a rapid 
detector of change and allows for early intervention such as retraining or continued 
observation, which is especially useful in its application in trainee programs.(26, 27) It 
has become an accepted method for monitoring performance in medical therapeutic 
and diagnostic procedures. (20, 24, 28, 29) The diagnostic error rate can be used as a 
measure for overall diagnostic performance in learning curves.(20) This rate does not 
distinguish between sensitivity and specificity, which are discussed in another paper.(17)
The OCT-trainees reported their diagnosis on a 5-point confidence scale, which enabled 
us to monitor performance for different thresholds for a positive test result for OCT. 
Since a score of ‘3’ or more on the Likert-scale reflected the assessor being certain of 
the diagnosis BCC, we considered this as the most appropriate threshold. However, in 
a scenario in which the aim is not to miss a BCC, one may opt for a confidence level ≥ 
2 as the cut-off point for a positive test result. For the latter, the number of cases (183) 
that need to be evaluated before reaching acceptable performance was lower than the 
311 required scans when the more strict threshold ≥ 3 was used. A possible explanation 
is that less experienced OCT users tend to exercise more caution in their judgement, 
represented by lower confident scores, which is penalized when using a high confidence 
score as the cut-off value.
When the ultimate goal of OCT is to be able to omit punch biopsy, it becomes important 
to monitor the ability to make both accurate and confident diagnoses. However, such 
ability requires more and longer training.
The number of cases required to achieve acceptable performance depends strongly 
on the choice of the acceptable and unacceptable failure rates (p0 and p1). These 
parameters set the target that one wants to achieve and may differ between centres. 
But the setting of realistic targets for our centre, where OCT has not yet been 
implemented in clinical practice, was challenging. Diagnostic error rates of 12% have 
been reported by two (industry-initiated) studies on diagnostic performance of OCT.
(13, 14) However, the prevalence of BCC was higher than in our study and thus the study 
populations may represent a different case mix. Moreover, the level of confidence in the 
OCT diagnosis used to define a positive test result of OCT was not explicitly reported 
in these studies.(13, 14) Therefore, efforts were made to obtain an estimate of the 
failure rate of a competent, experienced operator. For this purpose, two OCT users with 
23 and 8 years of experience (JW and SS) assessed a randomly chosen subset of 100 
scans of our database. The error rates of these OCT users were 16%. The setting of the 
unacceptable error rate at 25% was more straightforward, since this was the error rate 
accomplished by clinical examination in this study and in order to be of added value we 
felt OCT-assisted diagnosis should not exceed this rate.(17)
This study gives an indication of the number of cases that given our clinical, 
histopathological and OCT experience should be assessed with OCT before being able 
to discriminate BCC from other diagnoses. These results cannot be universally applied 
to other centres, because previous experience with OCT may differ as well as targets 
considered feasible or acceptable. In former studies, OCT training programmes (if 
described) consisted of a 30-minute instruction of 50 OCT images or a 20-minute lecture 
on OCT.(12, 16) In the current study, training was more extensive. We think that a basic 
level of background knowledge is necessary in order to understand the structures visible 
on the scans and a similar two-day course consisting of general lectures and hands-on 
training by experienced users is minimally required before starting to train with OCT 
in clinical practice.
CONCLUSION
Currently, no recommendations or guidelines on training in OCT exist. This study 
illustrates our experience with how a learning curve can help to establish the number 
of cases that are required to achieve an adequate level of performance. At an acceptable 
and unacceptable diagnostic error rate of 16% and 25%, adequate performance in 
diagnosing BCC was reached after 183-311 scans. So, it seems that a substantial number 
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SUPPLEMENTARY MATERIAL
Appendix 1: Formulas used in the construction of the CUSUM chart (20)
General CUSUM formula:
 is a score calculated from the probabilities of ‘success’ (p0) and probabilities of failure (p1):
Decision limits (h1) and (h0) are graphical boundaries which determine if a process is in 
or out of control and are calculated based on the risk of:
α: risk of type I error
β: risk of type II error
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CHAPTER 3
Minimal-invasive treatment in basal cell 
carcinoma: therapies and preferences 
CHAPTER 3.1
Surgery versus combined treatment with 
Curettage and Imiquimod for Nodular basal 
cell carcinoma (SCIN): 1-year results of a non-
inferiority, randomized controlled trial.
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Purpose: Nodular basal cell carcinoma (nBCC) is mostly treated with surgical excision. 
Interest in minimally invasive treatment of these low-risk tumors is increasing. We 
assessed the effectiveness of nBCC treatment with curettage and imiquimod cream 
compared with surgical excision.
Methods: Patients with nBCC included in this randomized, controlled noninferiority 
trial were randomly assigned to either a curettage and imiquimod cream group or 
a surgical excision group. The primary endpoint was the proportion of patients free 
from treatment failure 1 year after the end of treatment. A prespecified noninferiority 
margin of 8% was used. A modified intention-to-treat and a per-protocol analysis was 
performed (ClinicalTrials.gov identifier NCT02242929).
Results: One hundred forty-five patients were randomized: 73 to the curettage and 
imiquimod cream group and 72 to the surgical excision group. The proportion of 
patients free of recurrence after 12 months was 86.3% (63/73) for the curettage and 
imiquimod group and 100% (72/72) for the surgical excision group. The difference in 
efficacy was -13.7% (95% confidence interval -21.6% to -5.8%; 1-sided P = .0004) favoring 
surgical excision.
Conclusion: Noninferiority of curettage and imiquimod cream cannot be concluded. 
Given the still high efficacy of curettage and imiquimod cream and the indolent growth 
pattern of nBCC, curettage and imiquimod could still be a valuable treatment option 
with the possibility to prevent overuse of excisions. However, it cannot replace surgical 
excision.
INTRODUCTION
Basal cell carcinoma (BCC) is a slowly growing, locally invasive skin tumor and the most 
common malignant disease in white patients.1 A simplified histologic classification of 
BCCs distinguishes between nodular, superficial, and infiltrative variants, with nodular 
BCC (nBCC) being the most frequent subtype.2 Standard treatment of nBCC is surgical 
excision (SE). Because of the increasing incidence of BCC, its treatment puts a high 
burden on dermatologic practice. Superficial and nBCCs in low-risk areas are generally 
accepted to be low-risk tumors with a slow growth pattern and low invasive potential, 
which has encouraged research on the effectiveness of noninvasive and minimally 
invasive treatment options. Surgical excision may be accompanied by complications 
(postoperative bleeding, secondary infection, and disfiguring scars), which is even 
more relevant in patients who develop multiple BCCs.3 Noninvasive treatments, such 
as imiquimod cream, 5-fluorouracil, or photodynamic therapy are currently registered 
and commonly used for treatment of superficial BCC. Of those, imiquimod proved 
to be superior with clearance rates of 80.5% at 5 years after treatment.1,4 Imiquimod 
cream treatment for nBCC has been investigated in a randomized, controlled, double 
blind, dose response trial with a surgical excisional endpoint by Shumack et al,5 and 
optimal cure rates were found for once daily dosing for 7 days per week. Clearance 
was evaluated after treatment and cure rates were 71% and 76% after 6- and 12-
week daily treatment regimens, respectively.5 Recently, Williams et al6 compared the 
effectiveness of a 12- week imiquimod cream treatment regimen to surgical excision of 
low-risk superficial BCC and nBCC after 3 and 5 years of follow-up. Imiquimod already 
showed a high efficacy of 82.5% after 5 years of follow-up but was still inferior to 
surgery.6 A treatment strategy mentioned in guidelines for low-risk nBCC is curettage 
and electrodesiccation, but it often leads to a poor cosmetic result with hypertrophic 
scarring, probably because of the destruction after electrodesiccation.1,7,8 Curettage 
alone is not deemed an accepted treatment modality for nBCC.9 We hypothesized that 
combining the mechanic effect of curettage with the immunologic antitumor effect 
of imiquimod cream could enable a deeper penetration of imiquimod into the tumor. 
Combining curettage with imiquimod cream for nBCC was already investigated in some 
small phase II and III pilot studies, showing efficacy rates (initial and sustained tumor 
clearance) ranging from 94% to 100% with follow-up of 6 weeks to 1 year.10-12 We 
aimed to evaluate whether curettage followed by imiquimod cream 5% is noninferior 
to surgical excision in the treatment of patients with low-risk nBCC.
METHODS
A multicenter, randomized, controlled noninferiority trial was performed at the 
outpatient clinics of the Maastricht University Medical Centre, Maastricht, and 
Catharina Hospital, Eindhoven. Eligible patients had a primary nBCC of 4 mm to 20 




specimen.13 Mixed type BCCs having a superficial and nodular component were also 
included. One lesion per patient was included to ensure independence of observations. 
When patients had >1 BCC, the most accessible lesion or the largest lesion was chosen. 
Exclusion criteria were: localization in the H-zone of the face or on the hairy scalp, 
recurrent BCC and BCC with (partly) an aggressive histopathologic subtype (infiltrative, 
BCC with squamous differentiation), patient life expectancy of\5 years, breastfeeding 
or pregnancy, serious comorbidities (overall health status/diseases of the patient 
that makes follow-up impossible), genetic skin cancer syndromes, or the use of 
immunosuppressive medication during the trial period until 3 months after the end of 
treatment or within 30 days before enrollment. This trial was conducted in accordance 
with the Declaration of Helsinki. The protocol was approved by the local independent 
ethics committee and all patients provided written informed consent.
The primary study endpoint was the proportion of patients free from treatment failure 
1 year after the end of treatment, defined as the absence of residual tumor after 3 
months or of local recurrence after 1 year posttreatment.
Patients treated with imiquimod cream had a follow-up visit scheduled at 3 months 
and both treatment groups had a visit at 12 months after treatment. Two investigators 
independently examined patients for clinical signs (shiny border, telangiectasia, 
and ulceration) and dermoscopic characteristics (telangiectasia or ovoid nests) of 
residual or recurrent tumor as is usually done in standard care. In the event that one 
of the investigators suspected initial treatment failure or recurrence, a 3-mm punch 
biopsy specimen was obtained for histologic verification. Only in cases of histologic 
confirmation of BCC was the lesion considered as a treatment failure.
Secondary endpoints were compliance, cosmetic outcomes, patient satisfaction, 
and pain and adverse events 1 year posttreatment. Cosmetic outcome was assessed 
independently by 2 investigators and the patients on respectively a 4-point scale (poor, 
fair, good, or excellent) and patient and observer scar assessment scale.14
Patients were asked for adverse reactions during follow-up visits, completed diaries 
to report daily on compliance and pain (on a 10-point visual analogue scale where 0 
represents ‘‘no pain’’ and 10 represents the ‘‘most severe pain imaginable’’) during 
treatment and 2 weeks after treatment. Patient satisfaction was evaluated by asking 
3 standard questions.
Procedures
Patients allocated to surgical excision could undergo this procedure on the day of 
randomization. The nBCC was excised under local anesthesia (lidocaine 1%) with a 
3-mm clinically tumor-free safety margin into the subcutaneous fat.15 Sutures were 
removed 1 to 2 weeks postoperatively, depending on tumor localization. Histologic 
examination was performed by pathologists on tumor margins using postoperative 
hematoxyline eosin-stained vertical sections taken from formalin-fixed, paraffin-
embedded tissue. Patients assigned to the curettage and imiquimod 5% cream group 
underwent curettage only of the elevated tumor tissue, up to the level of normal skin 
at the day of randomization. To allow healing of the erosion, imiquimod 5% cream was 
started 1 week after curettage. The dosing regimen was a 6-week application, 5 days 
a week, once a day. Patients were instructed to apply the cream in a thin layer on the 
tumor including 5 mm to 10 mm of the surrounding skin, to use no occlusive dressing, 
and to apply the cream at least 1 hour before going to bed and to wash it off the next 
morning. All suspected unexpected serious adverse reactions were recorded in the 
national registry (toetsingonline.com).
Randomization and masking
Patients were randomly assigned to either topical imiquimod 5% cream and curettage 
or surgical excision groups using a computer-generated randomization list with random 
permuted blocks of 4. Randomization was stratified for participating center. Blinding of 
patients and physicians to treatment assignment was not feasible because of different 
scarring.
Statistical analysis
The prespecified noninferiority margin was set at 8% (assuming an efficacy of 98% after 
surgical excision and considering that curettage with imiquimod 5% cream is inferior 
if the efficacy would fall below 90%). A sample size of 130 patients (65 per group) was 
required to be 90% sure that the lower limit of a 2-sided 95% (1-sided 97.5%) confidence 
interval would exclude a difference in favor of the standard group of [8%. To account 
for a loss to follow-up of 10%, 144 patients were needed. The absolute difference in 
the proportion of participants without treatment failure between randomized groups 
at 1 year posttreatment was calculated with a 2-sided 95% confidence interval (95% 
CI). Negative differences indicate lower success rates for curettage with imiquimod 5% 
cream compared with excision. Both an intention to treat and a per protocol analysis 
were performed. Differences in secondary endpoints were calculated with the chi-
square test and t test for independent samples. All data were analyzed with SPSS 
software (v 23.0; IBM Corp, Chicago, IL). This study is registered on clinicaltrials.gov 
(NCT02242929).
RESULTS
Between January 2016 and November 2017, 310 patients were assessed for eligibility 
(Fig 1). Of those, 165 declined to participate because of a strong preference for 1 of 
the 2 treatments, difficulties to apply cream because of lesion location, older age, or 
comorbidities. The BCC size of patients declining participation were comparable to 




randomly assigned to treatment with either curettage and imiquimod cream (n = 73) or 
surgical excision (n = 72) in 2 hospitals: Maastricht University Medical Centre (n = 137) 
and Catharina Hospital Eindhoven (n = 8). All patients received the allocated treatment. 
Four patients (2.8%) were lost to follow-up (Fig 1). Baseline characteristics are shown 
in Table I. There were slight imbalances between the treatment groups, with higher 
frequencies of female sex, Fitzpatrick skin type 1, and location of the lesion in head and 
neck region in the patients assigned to the curettage and imiquimod group. Positive 
history of BCC was less often reported in this group.
Primary endpoint
One year after treatment, the proportion of patients free from treatment failure was 
86.3% (63/73) for the curettage and imiquimod cream group and 100% (72/72) for the 
surgical excision group.
Fig 1. Study flowchart









 Male 77 (53.1%) 33 (45.2%) 44 (61.1%)
 Female 68 (46.9%) 40 (54.8%) 28 (38.9%)
Age in years median (range) 68 (31-89) 68 (38-89) 67 (31-87)
Skin type
 I 55 (37.9%) 35 (47.9%) 20 (27.8%)
 II 90 (62.1%) 38 (52.1%) 52 (72.2%)
History of BCC
 Yes 89 (61.4%) 38 (52.1%) 51 (70.8%)
 No 56 (38.6%) 35 (47.9%) 21 (29.2%)
Sun exposure
 Mild 1 (0.7%) 0 (0%) 1 (1.4%)
 Moderate 121 (83.4%) 58 (79.5%) 63 (87.5%)
 Severe 23 (15.9%) 15 (20.5%) 8 (11.1%)
Size BCC
Median in mm (range) 7 (4-20) 8 (4-20) 7 (4-20)
≤7mm 75 (52.8%) 34 (46.6%) 41 (59.4%)
>7mm 67 (47.2%) 39 (53.4%) 28 (40.6%)
Location
 Head/Neck 43 (29.7%) 25 (34.2%) 18 (25%)
 Trunk 56 (38.6%) 25 (34.2%) 31 (43.1%)
Upper extremities 23 (15.9%) 12 (16.4%) 11 (15.3%)
Lower extremities 23 (15.9%) 11 (15.1%) 12 (16.7%)
Study site
 Maastricht 137 (94.5%) 69 (94.5%) 68 (94.5%)
 Eindhoven 8 (5.5%) 4 (5.5%) 4 (5.5%)
The absolute difference was -13.7% (95% CI -21.6% to -5.8%; 1-sided P = .0004) favoring 
surgery. The lower limit of the 95% CI exceeds the noninferiority margin of -8% and so 
it cannot be concluded that curettage with imiquimod is noninferior to surgical excision 
(Fig 2). Per-protocol analyses resulted in similar results with an absolute difference of 
-12.5% (95% CI -20.1% to -4.7%; 1-sided P = .0009). Residual or recurrent tumors in the 




and lower extremities (n = 2). Histopathology showed 1 superficial, 7 nodular, and 2 
aggressive BCCs (1 infiltrating, 1 basosquamous).
Fig 2. Absolute difference in efficacy between curettage and imiquimod versus surgical excision. 
The figure shows the absolute difference in treatment efficacy 1 year after treatment (-13.7%) and 
the horizontal line represents the 95% confidence interval (-21.6% to -5.8%). The lower boundary 
of the 95% confidence interval crosses the noninferiority limit of -8%.
Subgroup analyses
The median value of BCC size (7 mm) was used as the cutoff for subgroup analyses of 
the nBCC size. For patients with BCCs ≤7 mm, the absolute difference was -14.7% (95% 
CI -26.6% to -2.8%; 1-sided P = .008), and for patients with BCCs >7 mm the difference 
was -12.8% (95% CI -23.3% to -2.3%; 1- sided P = .03), both in favor of surgical excision.
Secondary endpoints
The proportions of patients with residual tumor at 3 months after treatment were 6.8% 
(5/73) in the curettage and imiquimod group and 0% (0/72) in the surgical excision 
group (1-sided P = .030). Pain scores revealed that patients treated with curettage and 
imiquimod cream less often reported moderate to severe pain (13.5%) compared with 
patients in the excision group (27%), but the differences were nonsignificant (P = .208; 
Table II). The proportions of patients receiving curettage and imiquimod that reported 
moderate to severe adverse events varied from 1.7% (for squamae) to 30% (for redness) 
(Table II). Patients did not report flu-like symptoms in their diaries.
Table II. Pain and adverse events during and 2 weeks after treatment reported by patients*
Pain score (VAS) Curettage and imiquimod Surgery
Absent/mild 51/ 59(86.4%) 38/52 (73%)
Moderate 6/59 (10.2%) 11/52 (21%)
Pain score (VAS) Curettage and imiquimod Surgery
Absent/mild 51/ 59(86.4%) 38/52 (73%)
Severe 2/59 (3.4%) 3/52 (6%)
Curettage and imiquimod treatment
Adverse events
Absent/mild Moderate/severe
Redness 42 (70%) 18 (30%)
Erosion 45 (75%) 15 (25%)
Crusts 45 (75%) 15 (25%)
Squamae 59 (98.3%) 1 (1.7%)
Itching 57 (95%) 3 (5%)
VAS, Visual analogue scale.
*Pain and adverse events were recorded in diaries, so data were missing for some participants. 
Pain scores are categorized into 3 groups: absent/mild, 0-3; moderate, 4-6; and severe, 7-10. 
Adverse events are categorized into 2 groups: absent/mild and moderate/severe.
No suspected unexpected serious adverse events occurred in this study. Data on 
cosmetic outcomes are shown in Table III. Investigator-reported cosmetic outcome 
after curettage and imiquimod was significantly better than after surgical excision, but 
patient ratings of cosmetic results were similar in both treatment groups (Table III). 
An exception concerned the subgroup of BCCs located in the head and neck, where 
the patient reported that cosmetic outcome was significantly better after curettage 
and imiquimod than after surgical excision (P = .02). Patient satisfaction results are 
shown in Table IV. Compliance was 100% in the excision group. Complete compliance 









Four point scale (N (%)) Good/excellent Good/excellent
Observer 1 61/71 (85.5%) 47/69 (68.1%) 0.012
Observer 2 59/71 (83.1%) 31/68 (45.6%) <0.001
Patient 67/67 (100%) 60/63 (95.2%) 0.071
POSAS researchers
Mean (standard deviation)
Overall opinion Overall opinion
Observer 1 2.3 (1.8) 3.4 (1.9) 0.001
Observer 2 2.7(2.0) 4.2 (2.6) <0.001
Patient 2.0 (1.7) 2.4 (2.0) 0.282
POSAS, Patient and Observer Scar Assessment Scale; SD, standard deviation.





I would undergo this treatment again
I agree 57 (85.1%) 63 (95.5%)
I do not agree 8 (11.9%) 2 (3%)
I do not know 2 (3%) 1 (1.5%)
I would recommend this treatment to others
I agree 59 (88%) 57 (86.4%)
I do not agree 3 (4.5%) 2 (3%)
I do not know 5 (7.5%) 7 (10.6%)
I am satisfied about the cosmetic result
I agree 59 (88%) 64 (97%)
I do not agree 4 (6%) 1 (1.5%)
I do not know 4 (6%) 1 (1.5%)
DISCUSSION
Surgical excision was significantly more effective than curettage and imiquimod 
in this study. With a difference of -13.7% and the lower limit of the CI falling below 
the prespecified noninferiority margin of -8%, it cannot be concluded that curettage 
followed by imiquimod cream is noninferior to surgical excision. This conclusion also 
holds for smaller nBCCs (≤7 mm). The probability of being free from treatment failure 
at 1 year after the end of treatment was 86.3% and comparable to the 1-year success 
rate of 85.6% that was found in the excisional surgery versus imiquimod 5% cream for 
nodular and superficial basal cell carcinoma (SINS) trial for the subgroup with nBCC. No 
curettage was performed in the SINS trial, but imiquimod treatment was applied for 
12 weeks instead of 6 weeks. Previous phase II to III pilot studies already found higher 
efficacy rates of 94% to 100% after curettage and imiquimod in the treatment of nBCC. 
However, these studies had shorter follow-up, used study populations that also included 
patients with superficial BCC, or applied imiquimod during a longer period (≤12 weeks 
of treatment).10-12 The similar success rates after imiquimod treatment of nBCC in this 
trial and the SINS trial raise the question whether the addition of curettage increases 
the effectiveness of imiquimod treatment. Curettage may allow for a shorter imiquimod 
application period of 6 weeks instead of 12 weeks, but this needs to be investigated. 
This trial does not allow the conclusion that imiquimod treatment with curettage 
is noninferior to surgical excision. Nevertheless, the success rates of curettage and 
imiquimod still represent a substantial response. In international guidelines, noninvasive 
treatment is already generally accepted as standard care for superficial BCC. There 
seems to be no obvious reason to follow another approach for nBCC than for superficial 
BCC, because both subtypes are considered low risk and in the SINS trial 3-year clearance 
rates for nBCC were not much lower than for sBCC (81.8% and 85.1%, respectively). The 
high incidence of BCC puts a burden on the workload of dermatologists, and therefore 
curettage and imiquimod can be a valuable treatment alternative. Especially in patients 
with multiple lesions, this treatment increases capacity and might be cost effective. 
We found that clinical observers rated the cosmetic outcomes after curettage and 
imiquimod 5% cream significantly better than after surgery.
Patients reported that the cosmetic outcomes of curettage and imiquimod were 
significantly better for nBCC localized in the head and neck region compared with 
excision. The visibility of this region and the possible avoidance of reconstructive 
surgery can be causes for this finding. There were no flu-like symptoms reported. This 
is possibly because imiquimod cream was only applied to 1 small, solitary lesion.
A limitation of our study is that a total of 53.2% of the patients eligible for this study 
did not want to participate. Although it seems unlikely that this selection bias affects 
the estimate of efficacy, this problem, common to randomized controlled trials, may 
threaten external validity.
A second limitation is that no adjustment was possible for the slight imbalances in 
the baseline characteristics between the randomized groups because of the lack of 
treatment failures in the excision group. Randomization ensures that the allocation 
of treatment to patients is left purely to chance, but there is no guarantee that all 




is the 1-year follow-up period. Longer observation is required to ensure that late 
recurrences are not missed. However, the 5-year results in the SINS study showed that 
most treatment failures were identified early within the first year after treatment and 
that recurrences of low-risk BCC after topical imiquimod did not appear to be difficult 
to treat.6 Overall, in the treatment decision for nBCC the benefits of curettage and 
imiquimod should be weighed against the decrease in effectiveness compared with 
excision. Given the still high efficacy and the fairly indolent growth pattern, curettage 
and imiquimod could still be a valuable treatment option in nBCC, with the possibility to 
decrease the workload in clinical practices. It cannot, however, replace surgical excision 
as the first treatment choice. We thank MEDA pharma for donating 5% imiquimod cream 
free of charge. We thank Kiki Frencken for her enthusiasm and her contribution to the 
design of this study.
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INTRODUCTION
Basal cell nevus syndrome (BCNS, Gorlin syndrome) is a rare inherited disorder 
characterized by the development of multiple basal cell carcinomas (BCCs), odontogenic 
keratocysts, and palmar pits.1
BCC development is caused by sonic hedgehog pathway (SHH) activation caused by 
mutations in tumor suppressor gene patched 1 (PTCH1) or activating mutations in the 
oncogene smoothened (SMO).2 Because patients with BCNS carry a germ-line mutation 
in PTCH1, one additional somatic mutation (second hit) results in BCC development at 
a young age.
In 2012, the US Food and Drug Administration approved vismodegib for treatment of 
locally advanced BCC (laBCC) or metastatic BCC (mBCC). Vismodegib prevents activation 
of the SHH pathway by binding and inhibiting the SMO protein.3 Vismodegib resistance, 
mainly caused by SMO mutations, is an important problem seen in laBCC or mBCC in 
patients with and without BCNS.4, 5 Vismodegib resistance in smaller BCCs, which 
are far more frequent in BCNS patients, is only described once.6 Here, vismodegib 
resistance of those smaller BCCs in a BCNS patient is genetically explained, and a clinical 
treatment approach is given.
Case report
A 59-year-old man with BCNS (Gorlin syndrome) was seen at our dermatology 
outpatient clinic with a history of multiple BCCs, palmar pits, and hypertelorism. After 
former extensive mutilating surgical procedures, surgery was not feasible. Vismodegib 
treatment was started at 150 mg/d in a clinical trial (STEVIE; NCT01367665). There was 
a reduction of the amount and size of the BCCs until no BCCs were clinically detectable 
and also palmar pits disappeared (Fig 1, A and B). Adverse events included hair loss, 
muscle cramps, a total lack of taste, and weight loss of 15 kg. After 3 years of continuous 
vismodegib therapy, 3 lesions developed (preauricular and 2 on his back) suspect for 
recurrent BCC (Fig 1, C). After excision of the 3 lesions, 2 lesions (preauricular and on his 
back) were histologically confirmed to be superficial BCCs, whereas one of the lesions 
on his back showed no histologic signs of malignancy. Following the study protocol, 
treatment was discontinued (resistance). Written informed consent was obtained to 
perform genetic analysis on their tissue.
Two months after discontinuing vismodegib treatment, multiple BCCs (re)developed on 
their original locations and with the exact sizes as before treatment. Currently, he is 
treated intermittently with vismodegib (4-5 months on and 6-7 months off), depending 
on response and side effects. Resistant tumors are surgically excised at the end of each 
treatment cycle.
Figure 1
BCNS patient. A, Before starting vismodegib. B, Clearance after 3 months of vismodegib 
treatment. C, BCC redevelopment (resistance).
METHODS
Directly after excision, biopsy samples (3 mm) were taken from the 3 clinically suspect 
BCCs preauricular and on the back. The samples were freshly frozen and stored at 
e808C, and subsequently DNA was extracted (DNeasy Blood & Tissue Kit, Qiagen, Hilden, 
Germany) and analyzed using single molecule molecular inversion probes (smMIPs).7
An smMIP-based library preparation was used to target coding sequences of genes 
involved in the SHH pathway: PTCH1, PTCH2, SMO, SUFU, GLI2, and TP53(resp. NCBI 
RefSeq: NM_000264.3, NM_ 003738.4, NM_005631.4, NM_016169.3, NM_0052 70.4, 
M_000546.5/NM_001126113.2/NM_0011261 14.2). Subsequently, the samples were 
sequenced on a MiSeq system (Illumina, San Diego, CA) nextgeneration sequencer.
4.2
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RESULTS
Table I. Mutational analysis: Resistant basal cell carcinomas analyzed using molecular inversion 
probes
Sample Mutation Gene Protein change Type
Sample 1 (BCC) c.747-2A>G
59.8%
PTCH1 p.?1 Germ line splice site mutation with 
LOH of other allele (skewed %)
Sample 1 (BCC) c.1417G>A
14.1%
SMO p.Asp473Asn Somatic missense mutation 
(responsible for vismodegib 
resistance)
Sample 2 (BCC) c.747-2A>G
47.4%
PTCH1 p.?1 Germ line splice site mutation
Sample 2 (BCC) c.1804C>T
26.8%
PTCH1 p.Arg602* Somatic nonsense mutation
Second hit
Sample 2 (BCC) c.1406G>A
23.5%
SMO p.Cys469Tyr Somatic missense mutation 
(responsible for vismodegib 
resistance)
 Sample 2 (BCC) c.722C>T
26.4%






PTCH1 p.?1 Germ line splice site mutation
1 The germ line mutation is located at the splice acceptor site of intron 5 (at the exon 6 border). 
Splice site software tools (integrated in the Alamut V2.10 software) predict the acceptor splice 
site to be lost by the mutation. Since the mRNA cryptic splicing needs to be experimentally 
verified, the resulting putative protein is unknown (p.?).
All 3 samples showed a germ-line mutation in PTCH1, located in the splice acceptor site 
of intron 5, c.747-2A>G and predicted to affect the conical splice site, which putatively 
results in aberrant splicing of the PTCH1 transcript and is presumably causal to BCNS. 
The represented percentage of this PTCH1 mutation was 47.0% for histologically normal 
skin, and no additional mutations were found (sample 3). In sample 1 (BCC), the germ-
line PTCH1 mutation skewed to 59.8%. Furthermore, a SMO mutation c.1417G>A 
(p.(Asp473Asn)) was detected, representing 14.1% in the sample and a known mutation 
causing vismodegib resistance.4 In sample 2 (BCC) the PTCH1 germ-line mutation 
percentage was 47.4%, similar to that of normal skin. Additionally, a second nonsense 
mutation in PTCH1 c.1804C>T (p.(Arg602*)) was detected as second hit (26.8%). In this 
sample, a different causal SMO mutation c.1406G>A (p.(Cys469Tyr)) was found (23.5%).5 
Furthermore, a TP53 mutation c.722C>T(p.(Ser241Phe)), previously described as germ-
line mutation in sarcoma, was found (Table I).8
DISCUSSION
Here, a BCNS patient with vismodegib resistance in small, BCNS-related BCCs and the 
clinical course are described. To our knowledge, resistance of non-laBCCs was only 
documented in 1 of the 41 included BCNS patients in a phase 2 trial by Tang et al6 This 
resistance is probably much less frequent than vismodegib resistance in laBCC, which 
occurs in approximately 20% of patients.9
Both detected SMO mutations in the resistant BCCs were found before.4, 5 The few 
different SMO mutations reported to date suggest the presence of hotspot regions 
in SMO, responsible for resistance.4, 5 We used smMIP-based analysis, because it is 
relatively easy in determining SMO-associated tumor resistance with low costs.7 In a 
clinical setting, this may be valuable and even cost effective if the decision to continue 
therapy depends on one or a few lesions. Vismodegib resistance in BCNS does not have 
the same clinical implications as in laBCC/mBCC, because the few resistant BCCs can 
easily be treated otherwise.
Vismodegib discontinuation led to reoccurrence of BCCs at their original locations, 
suggesting that tumors are not completely eliminated. Indolent cancer stem cells, 
capable of redeveloping cancer cells when treatment is discontinued are hypothetically 
debit.4 The fact that treatment with vismodegib is only of suppressive nature is 
important to discuss with the patient.
In BCNS patients with non-laBCCs only, 17% tolerate continuous vismodegib treatment 
during 3 years, and side effects are the major reason for discontinuation of treatment.6 
In these patients with long-term treatment need, rotational schedules have been applied 
(12 weeks of 150 mg/d vismodegib rotated with 8 weeks of placebo, or starting with 
24 weeks vismodegib followed by 8 weeks of placebo rotated with 8 weeks vismodegib), 
but even then, adverse events cause high treatment discontinuation (23%).10 Probably, 
these schedules are still too stringent. Because BCNS patients need lifelong treatment, 
intermittent vismodegib therapy seems preferable and can be combined with excision 
or topical treatment of the few resistant tumors. In our experience, the development 
of response and severity of side effects varies, so discontinuation and restart of the 
therapy should be guided by the burden of the patient.
4.2
120 121
Vismodegib resistance in BCNSChapter 4.2
REFERENCES
1. Bresler S.C., Padwa B.L., Granter S.R. Nevoid basal cell carcinoma syndrome (Gorlin 
syndrome) Head Neck Pathol. 2016
2. Epstein E.H. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 
2008;8(10):743–754.
3. Erdem G.U., Sendur M.A., Ozdemir N.Y., Yazici O., Zengin N. A comprehensive review 
of the role of the hedgehog pathway and vismodegib in the management of basal 
cell carcinoma. Curr Med Res Opin. 2015;31(4):743–756.
4. Atwood S.X., Sarin K.Y., Whitson R.J. Smoothened variants explain the majority of 
drug resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):342–353.
5. Sharpe H.J., Pau G., Dijkgraaf G.J. Genomic analysis of smoothened inhibitor 
resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):327–341.
6. Tang J.Y., Ally M.S., Chanana A.M. Inhibition of the hedgehog pathway in patients with 
basal-cell nevus syndrome: final results from the multicentre, randomised, double-
blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1720–1731.
7. Eijkelenboom A., Kamping E.J., Kastner-van Raaij A.W. Reliable next-generation 
sequencing of formalin-fixed, paraffin-embedded tissue using single molecule tags. 
J Mol Diagn. 2016;18(6):851–863.
8. Toguchida J., Yamaguchi T., Dayton S.H. Prevalence and spectrum of germline 
mutations of the p53 gene among patients with sarcoma. N Engl J Med. 
1992;326(20):1301–1308.
9. Chang A.L., Oro A.E. Initial assessment of tumor regrowth after vismodegib in 
advanced Basal cell carcinoma. Arch Dermatol. 2012;148(11):1324–1325.
10. Dreno B., Kunstfeld R., Hauschild A. Two intermittent vismodegib dosing regimens 
in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-





Discussion and valorisationChapter 5
This thesis describes the results of multiple studies concerning the minimally and non-
invasive diagnosis and treatment of basal cell carcinoma (BCC). In this chapter the major 
conclusions of this thesis will be summarized. The results will be discussed and the 
relevance for clinical practice will be outlined.
Why this research is relevant
The incidence of basal cell carcinoma (BCC) is increasing with a current life time risk 
of 1 in 5-6 people in the Netherlands.(1) In practice, these patients often develop 
multiple BCCs due to sun-damaged skin .(2) One of the main causes potentially lies in 
the recreational sun behaviour in the 60s and 70s without the use of sun protection. 
Today, the consequences of this behaviour become visible with a high incidence of sun 
damaged skin (actinic keratosis) and the development of non-melanoma skin cancer; 
basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).(3) Although, there is 
more attention and awareness of the negative effects of UV radiation nowadays, an 
increase of BCC is seen in the younger population (below the age of 40 years) over the 
last years.(4) It seems that getting a tan, by either sunlight or a sun bed is still seen 
as attractive to many people. Furthermore, people do not seem to associate cycling, 
walking and outdoor swimming to increased sun exposure. In addition, as people get 
older, an increase in BCC incidence is expected over the next years. So, even more 
awareness is necessary to change the current sun behaviour of people and hopefully 
decrease the incidence of BCC in the future. Until then, it is important to optimize 
diagnosis and treatment of BCC to provide the most optimal care for patients. As far 
as diagnosis and treatments are concerned, minimally and non-invasive options are 
being sought and investigated.
Although BCCs are considered to be skin cancers, especially the superficial and nodular 
subtypes have fairly indolent characteristics: these BCCs grow slow, hardly ever 
metastasize and do not influence life expectancy. Still, longer existing tumours can grow 
into deeper tissues and can cause persisting wounds. Moreover, several other subtypes 
(micronodular, morpheaform) are associated with a more aggressive growth. Therefore, 
correct diagnosis to guide decisions on optimal treatment is essential. Aggressive BCCs 
(i.e. micronodular, morpheaform) require surgical excision, but in recent years there has 
been a trend toward the development of non-invasive and less invasive methods for 
the treatment of less aggressive BCCs (superficial, nodular). Given the high volume of 
BCC in dermatological practices, less and non-invasive diagnostic tools and treatments 
provide the opportunity to reduce the work load for dermatologists caused by the high 
number of biopsies and surgical excisions. Besides, it would be possible to give patients 
more control over their own treatment. Herewith , we (clinicians) must remain critical 
regarding the application of non-invasive diagnostic methods and treatments in clinical 
practice, in a way that accuracy and effectiveness remains warranted. In this context, we 
have to keep searching for new technologies and treatments that will make healthcare 
not only more efficient, but also more patient friendly.
Diagnosis of basal cell carcinoma
Over the years the carcinogenic aspect of basal cell carcinoma, especially of superficial 
and nodular basal cell carcinoma has been increasingly questioned. Since these types 
of BCC hardly metastasize (0.0003-0.55%) and grow slowly, the question is whether 
invasive diagnosis and treatment is still necessary.(5) Being an indolent form of skin 
cancer it gives clinicians the opportunity to look out for different types of diagnostic 
tools to diagnose BCC. Currently, a skin biopsy is the first choice when it comes to 
BCC diagnosis and subtyping.(6) Obtaining a biopsy is an invasive procedure which can 
cause pain and bleeding during the procedure and complications such as infection and 
scarring afterwards. Histopathological assessment takes approximately 1 week and 
during this period the uncertainty may cause stress for patients. Moreover, it results in 
a treatment delay since treatment will not be started before definitive histopathological 
results are available.
Within the dermatology field, various alternative, non-invasive imaging techniques are 
in development. In the Netherlands, there is much experience with reflectance confocal 
microscopy (RCM, Vivascope), in research settings. RCM is a non-invasive technique, that 
is currently not yet ready for clinical use by general dermatologists, because it is difficult 
to use or interpret.(7, 8) Compared to RCM, OCT has the advantage that images are 
shown in a vertical plane and therefore resemble histological slides making them easier 
to interpret. Besides that, penetration of the OCT is deeper, giving more information 
about deeper invading subtype or depth of the tumour. These characteristics together 
with specific BCC characteristics seen on the OCT image makes it a more usable option 
in clinical practice.
Clinical examination alone is already associated with a high sensitivity of at least 90% 
to diagnose a BCC.(9, 10) Specificity of clinical examination is known to be low, 28.6% 
as shown in the study by Ulrich et al. These authors compared the diagnostic accuracy 
of clinical and dermatoscopic evaluation of suspected lesions with that of OCT using 
histopathological results as gold standard.(10) The low specificity is probably the main 
reason why the number of biopsies taken in patients who do not have BCC is still high.
In order to reduce the amount of biopsies in the future, OCT should offer a better 
accuracy than clinical examination. In Chapter 2.1 we conducted a clinical cohort 
study comparing clinical examination alone to OCT using biopsy as gold standard test 
in the diagnosis and subtyping of BCC. We found that the accuracy of diagnosing BCC 
improved when OCT (together with clinical photographs of the lesion) was used. The 
area under the ROC curve was 91.2% as compared to 85.6% after clinical examination 
alone (P=0.061). The specificity increased significantly with the use of OCT (76.8%) 
as compared to clinical examination (47.5%) at similar sensitivity (95.2% and 97.6%, 
respectively). These results confirm that OCT can be a promising new method to confirm 
the diagnosis of a BCC if there is still doubt after clinical evaluation. However, it showed 
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that subtyping of BCCs is still difficult with OCT. If it had been f feasible to evaluate 
the OCT scans directly, alongside the patient in the study, the ability to discriminate 
between nodular BCC and other BCC subtypes might have been better, because nodular 
BCCs are clinically well recognizable and have characteristic features such as elevation, a 
pearly translucent margin, and telangiectasia. The typical shiny appearance of a nodular 
BCC is even better seen when a light beam is moved over the tumour. Due to the design 
of the study, the assessors of OCT images had to do with photographs of the lesion in 
which elevation and shiny appearance are obviously less clear.
Another explanation for the difficulty in subtyping could be the still limited resolution 
of OCT, which makes it more difficult to differentiate in cases where subtypes show 
overlap. Often it is difficult to determine if a BCC is only superficial or already starting to 
become nodular (mixed subtype). However, this is a shared problem with histopathology 
and this will remain a matter of clinical interpretation.
When the use of OCT is evolving, it is most likely that in part of the patients biopsies 
could be avoided in the future. If a biopsy can be avoided by accurate OCT diagnosis 
of BCC, the BCC diagnosis could be discussed on the same day and treatment could be 
started or planned directly. This is more convenient for the patients and it may also 
reduce anxiety and stress. This is an already existing concept and is called the one-
stop-shop concept.
We found that the percentage of biopsies that could be avoided in the future is around 
30%. However, it is important to realize that inaccurate diagnosis by OCT which is not 
verified by punch biopsy harbours the risk of over- or under treatment. Further research 
is necessary to find out whether the accuracy of OCT improves even more when scans 
are evaluated in a clinical setting and whether use of OCT actually reduces the necessity 
of a biopsy in clinical practice. The study discussed in chapter 2.1 was the basis for a 
multicentre randomised controlled trial which is currently ongoing with the Maastricht 
UMC as the coordinating centre. This randomised controlled trial directly compares 
OCT-guided diagnosis and treatment with standard care, where a biopsy is always taken 
to verify the clinical diagnosis. It evaluates whether effectiveness in terms of remaining 
free from recurrences in the long term is comparable between the two study arms.
4Accuracy of diagnosing BCC with OCT can improve with training. Therefore, with the 
use of learning curves we investigated the number of OCT assessments necessary to 
reach an adequate level of performance (chapter 2.2). Cumulative sum analyses showed 
that an acceptable performance was reached after assessing 183 to 311 scans. The 
minimal number of OCT scans that need to be assessed depends on pre-set acceptable 
and unacceptable error rates, but also on cut-off values for the definition of a positive 
test. The OCT-researchers reported their diagnosis on a 5-point confidence scale, which 
enabled us to monitor performance for different thresholds for a positive test result for 
OCT. In a scenario where the aim is not to miss a BCC, one may opt for a confidence level 
≥ 2 (either high suspicion or certainty of BCC presence) as the cut-off point for a positive 
BCC diagnosis according to OCT. In this scenario the required number of 183 cases that 
need to be evaluated before reaching acceptable performance was lower compared 
with a scenario using a more strict threshold of ≥ 3 (only certainty of BCC presence was 
defined as a positive test result). The latter threshold may be more appropriate when 
the ultimate goal of OCT is to be able to omit punch biopsy if OCT diagnosis is positive. 
Then it becomes important to monitor the ability to make both accurate and confident 
diagnoses. However, such ability requires more and longer training as was indicated 
by the finding that at least 311 OCT scans had to be evaluated to achieve competence.
These results cannot be universally applied to other centres, because previous 
experience with OCT may differ as well as targets that are considered feasible or 
acceptable. However, the learning curves in our study provide more insight into the 
learning process and the expertise required to master a new skill and therefore will be 
important for further use and implementation of OCT in clinical practice.
Treatment of basal cell carcinoma
The majority of basal cell carcinomas is still treated with surgical excision.(6) But 
the same discussion that plays a role in de diagnosis of BCC is also applicable to the 
treatment of BCC. Given the indolent growth pattern and the possibility of non-invasive 
diagnosis, this type of skin cancer is also well-suited for less invasive treatment. Cancer 
medicine is increasingly focussing on topical non-invasive treatments like imiquimod 
and 5-fluorouracil.(11) This development enables patients to treat themselves in an 
out-of- hospital setting. Besides, if there are more treatment options available, it will 
be possible for patients to choose the treatment they prefer most. With the excessively 
rising incidence of skin cancer, a second important advantage that treatment by patients 
themselves offers is relieving some of the pressure put on dermatological practices by 
reducing surgical excisions . We conducted a non-inferiority randomized controlled trial 
(Chapter 3.1) comparing the efficacy of imiquimod with prior curettage with that of 
surgical excision in patients with nodular BCC. A predefined non-inferiority margin of 
8% was used. One year after treatment, the proportion of patients free from treatment 
failure was 86.3% (63/73) for curettage and imiquimiod cream and 100% (72/72) for 
surgical excision. The absolute difference was -13.7% (95% CI: -21.6% to -5.8%, one-sided 
p=0.0004) favouring surgery. The lower limit of the 95% CI exceeds the non-inferiority 
margin of -8% and so it cannot be concluded that curettage with imiquimod is non-
inferior to surgical excision.
Over the years, more topical therapy options became available for the treatment of 
superficial BCC and nodular BCC, however, to date the efficacy does not equal that 
of surgical excision. An alternative therapy (that is not as effective as the standard 
treatment) is only acceptable if it has other advantages like better cosmetic outcomes, 
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less adverse events or other benefits that lead to more patient satisfaction. It was 
expected that minimal invasive treatment of nodular BCC by curettage and imiquimod 
would result in improved cosmetic appearance of treated skin compared to surgical 
excision. Remarkably, from the patient perspective there was no difference in cosmetic 
outcome, whereas the clinical investigators did value cosmetic appearance significantly 
better after curettage and imiquimod treatment than after surgical excision. This finding 
could be explained by a high number of older patients in the study population and in 
practice it seems that this group does not attach high value to cosmetic appearance. 
However, patients did care for the cosmetic appearance if the BCC was located at a 
visible part of the body: the head and neck area. In this area the cosmetic outcome of 
curettage and imiquimod was valued significantly better than after surgical excision.
Patients attach different values to different treatments, depending on the situation 
and location. The choice of treatment will possibly differ between patients, as they 
will have different needs and require different treatment approaches. In a discrete 
choice experiment (DCE) including patients inside and outside the trial (Chapter 3.2), 
we aimed to investigate which attributes of a treatment are important to patients and 
to elicit preferences. Based on important attributes like efficacy, cosmetic results, side 
effects and waiting period, patients could make a choice between surgical excision or 
curettage and imiquimod cream as a treatment option. Surgery was chosen most of 
the times (60%), whereas 40% of the patients chose curettage and imiquimod. The 
relative importance of the attributes cosmetic results, adverse events and efficacy 
were calculated. It showed that for both surgical excision and curettage and imiquimod 
efficacy was considered the least important attribute. The most probable explanation 
for this finding could be that the efficacy of both treatments was high, which may have 
geared patients to focus more on other aspects. The DCE helps us to gain more insight 
in what aspects of a treatment are most important to patients, which may differ from 
those of medical workers, because patients often have different goals or associations 
with different treatments. Therefore, cooperation with patients in future randomized 
controlled trials is essential. Especially, because nowadays, not only efficacy, but many 
other aspects play important roles in the choice for a treatment.
Overall, surgical excision is still the most effective treatment in the treatment of nodular 
BCC. It also offers other advantages such as the possibility of histological assessment of 
the excision specimen and short treatment duration. After treatment with curettage and 
imiquimod cream in our study, the proportion of patients without treatment failure at 1 
year follow-up of 86.3% was still very high. Also, in international guidelines, non-invasive 
treatment is already generally accepted as standard care for superficial BCC .(12) There 
seems to be no obvious reason to follow another approach for nodular BCC than for 
superficial BCC, since both subtypes are considered low risk. (13) Despite a slightly 
lower efficacy, curettage and imiquimod can be a valuable treatment alternative as the 
high incidence of BCC puts a burden on the workload of dermatologists,. Especially in 
patients with multiple lesions, this treatment increases capacity and might be more 
cost-effective.
Hedgehog inhibitors
Treatment of BCCs in basal cell nevus syndrome (BCNS) patients and high-frequency 
BCC (HF-BCC) patients remains a challenge in dermatology. Usually the problem is not 
the subtype or size of the BCC, but the development of a high number of BCCs in 
patients.(14) Patients often require many repeated surgical excisions, leaving them with 
multiple scars. Difficult localisations in the head and neck area or new BCCs in areas with 
many scars increase the complexity of treatment of BCNS patients.(15) Furthermore, 
patients will develop new BCCs for the rest of their lives. Altogether the burden is 
high. Non-invasive topical therapies like imiquimod or curettage and imiquimod could 
be alternatives for surgery, but not every subtype is suited for this approach. Besides, 
sometimes there are just too many lesions and it is difficult to treat this high tumour 
burden with regular therapy. Hedgehog inhibitors might offer a solution in this selected 
population.
The review in chapter 4.1 gives an reflection on the treatment with hedgehog pathway 
inhibitors (HPIs) in BCNS and HF-BCC patients. Treatment with oral hedgehog pathway 
inhibitors is initially effective, but adverse events, drug resistance and moderate efficacy 
undermine the potential for long-term use. Most studies have been carried out with 
patients who had locally advanced BCC (laBCC) or metastasized BCC (mBCC), among 
which were also patients with BCNS who had a locally or metastasized BCC.(16-18) 
Only one study specifically investigated the efficacy of vismodegib in BCNS patients 
with multiple small BCCs, in whom the treatment indication was not locally advanced 
or metastasized BCC.(19) This study showed a decreased frequency of new BCCs and 
remission of existing BCCs.
Patients on HPIs frequently discontinue their treatment due to adverse events. 
Diarrhoea, nausea, fatigue and hair loss are common side effects. Personalized medicine 
is the key word in these patients, who will develop new BCCs for the rest of their 
lives. Therefore it is important to adjust a treatment to the patient. Resistance and 
side effects need to be overcome with the development of new treatment strategies. 
Intermittent dosing of oral HPIs has been proposed to decrease the severity of side 
effects and to make continuation of treatment possible. One randomized controlled 
trial investigated intermittent dosing of vismodegib.(20) In this study patients were 
treated for a median duration of 16.8 months, which is longer than in the continuous 
oral HPI trials. Besides, HRQoL improved during and after the trial on the emotional 
well-being domain compared to baseline HRQoL. However, there are no data on efficacy 
or resistance with this intermittent treatment. Although the possibility for longer 
treatment seems promising, this was the only randomized trial which investigated 
intermittent dosing, so conclusions should be drawn with caution. To ensure efficacy 
5
130 131
Discussion and valorisationChapter 5
during temporary discontinuation a combination of HPIs with regular treatment could 
also be an option. Furthermore, topically applicable HPIs could be a solution for 
some patients requiring long-term treatment for multiple BCCs. Research on topically 
applicable HPIs is still scarce, but recently a phase 3 randomised controlled trial was 
started, investigating topical treatment with the hedgehog inhibitor patidegib for BCNS 
patients. The Maastricht University Medical Centre is one of the participating centres 
in this international multicentre study.
Drug resistance remains a major problem for laBCC or mBCC treated with vismodegib. 
Vismodegib resistance in BCNS with laBCC occurs in approximately 20% of patients.(21) 
However, vismodegib resistance in small BCCs (non laBCC or mBCC) is rare. In chapter 
4.2 we described a BCNS patient with multiple small BCNS-related BCCs who initially 
had a favourable response, but who developed vismodegib resistance over time. This 
is only the second case that describes vismodegib resistance in BCNS without laBCC/
mBCC, indicating its rarity. (15) Although this report shows that vismodegib resistance 
does occur in BCNS-related BCCs, it does not have the same clinical implications as 
in laBCC/mBCC, because the few resistant BCCs in BCNS can easily be treated with 
surgical excision or topical treatments. However, these results should be interpreted 
with caution, due to the low number of patients and scarce available research in this 
BCNS group.(19)
CONCLUSION
In this thesis we paved the way toward a more non-invasive diagnosis and treatment 
of basal cell carcinoma. Even though the options of new diagnostic tools like OCT and 
treatments like imiquimod with prior curettage are promising, optimisation is necessary. 
Personalized treatment becomes increasingly important and should be based on the 
number and characteristics of the BCCs, location on the body and personal patient 
preferences. Non-invasive management should become a part of this personalized 
treatment, because it gives patients more options and the possibility to be actively 
involved in the process.
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SAMENVATTING
Basaalcelcarcinoom (BCC) is de meest voorkomende vorm van huidkanker, ongeveer 
20% van de Nederlanders ontwikkelt ergens in het leven een BCC. Er wordt onderscheid 
gemaakt tussen drie subtypen : oppervlakkig, nodulair en agressief. Het subtype bepaalt 
voor een belangrijk deel welke behandeling het meest geschikt is. Hoewel chirurgie nog 
steeds de standaard behandeling is, is er momenteel een trend naar minder invasieve 
vormen van diagnose en behandeling. Als deze minder invasieve opties meer worden 
geïmplementeerd in de huidige klinische setting, kan dit de werklast voor dermatologen 
verminderen, kan de zorg patiëntvriendelijker zijn en kunnen de kosten van medische 
zorg in de toekomst worden verlaagd. In de dermatologie is het BCC bij uitstek geschikt 
voor een niet-invasieve aanpak omdat het een type huidkanker is met een indolent 
groeikarakter, een goede prognose en een uiterst klein risico op metastasering. Dit 
proefschrift richt zich op minimaal invasieve methoden voor diagnose en behandeling 
van het BCC, gepresenteerd in 6 onderzoeken.
In hoofdstuk 1 wordt een algemene introductie gegeven betreffende de onderwerpen 
die aan bod komen in dit proefschrift. Epidemiologie, ontstaanswijze, diagnostiek 
en behandeling van het BCC worden besproken. Ook wordt de behandeling van 
het basaalcelnaevus syndroom met vismodegib besproken. Daarnaast worden de 
doelstellingen van dit proefschrift beschreven.
Niet-invasieve diagnostische strategieën maken gedetailleerd onderzoek naar de 
architectuur van huidweefsel mogelijk te maken en hebben potentieel voor identificatie 
en subtypering van het BCC. Een van deze technieken is optical coherence tomografie 
(OCT) beschreven in hoofdstuk 2. OCT is een beeldvormende techniek met veilig laser 
licht, die direct in vivo dwarsdoorsnedes afbeeldingen maakt van de huid. Hiermee kan 
men ongeveer 1,5-2 mm diep ‘in de huid kijken’. Het is een patiëntvriendelijke methode 
waarbij de scanner op de huid kan worden gezet en binnen 30 seconden een afbeelding 
wordt gemaakt van de laesie. Deze informatie kan worden gebruikt ter identificatie en 
subtypering van basaalcelcarcinomen.
Om de aanvullende diagnostische waarde van OCT te evalueren, hebben we in 
hoofdstuk 2.1 een prospectieve cohortstudie uitgevoerd waarbij 182 patiënten met 
in totaal 250 laesies werden geïncludeerd . Hierbij bestond de klinische verdenking op 
niet-melanoom huidkanker of voorlopers hiervan. Alleen patiënten waarbij een biopt 
moest worden afgenomen voor de diagnose werden geïncludeerd. Het eerste doel van 
de studie was om vast te stellen of OCT als aanvulling op de klinische beoordeling het 
mogelijk maakt om beter onderscheid te maken tussen aan- en afwezigheid van BCC. 
Het tweede doel was om na te gaan of gebruik van OCT bij patiënten met BCC leidt 
tot een accurate diagnose van het histologische subtype. De mate van vertrouwen in 
de OCT diagnose werd geregistreerd op een vijfpuntschaal, waarbij score 0 duidde 
op zekerheid over afwezigheid van BCC en scores 1-4 op toenemende zekerheid over 
aanwezigheid van BCC. Voor het schatten van diagnostische parameters werd de 
histopathologische diagnose met het punch biopt als gouden standaard gebruikt.
Bij gebruik van OCT als aanvulling op de klinische beoordeling nam het vermogen om 
te discrimineren tussen BCC en niet-BCC toe. Bij diagnose op basis van de klinische blik 
was de oppervlakte onder de ROC curve (area under the curve) gelijk aan 85.6%. Bij 
aanvullend gebruik van OCT nam de area under the curve toe tot 91.2% (p = 0,061). 
Indien een positieve OCT uitslag werd gedefinieerd als enig vermoeden op de 
aanwezigheid van een BCC (Likert scale score 1-4), nam de specificiteit op patiëntniveau 
toe van 47,5% (alleen klinisch onderzoek) tot 76,8% (OCT) bij vergelijkbare sensitiviteit 
(respectievelijk 97,6% en 95,2%). OCT verbeterde tevens het vermogen om onderscheid 
te maken tussen oppervlakkige en niet-oppervlakkige BCC-subtypen.
In een aanvullende analyse werd onderzocht of een diagnose op basis van OCT 
nauwkeurig genoeg is om bij een positieve OCT uitslag een punch biopt achterwege te 
kunnen laten. Het voordeel is dat het dan niet meer nodig is om de uitslag van het biopt 
af te wachten en men in overleg met de patiënt direct kan overgaan tot een keuze voor 
behandeling. Voor deze analyse werden de patiënten geselecteerd bij wie de diagnose 
op basis van OCT een hoge zekerheid had voor de diagnose BCC en ook het subtype. 
Dit was het geval in 55 van de 182 patiënten (30%). Volgens histopathologie was er 
bij 49 van deze 55 patiënten (89.1%) inderdaad sprake van een BCC en in de overige 6 
gevallen betrof was het goedaardige aandoeningen. De consequenties van inaccurate 
diagnose op basis van OCT in termen van over- en onder behandeling lijken beperkt. 
Echter de vraag of OCT-geleide diagnose en behandeling van laesies met verdenking 
op BCC mogelijk is zonder de prognose van patiënten in gevaar te brengen kan alleen 
beantwoord worden met een gerandomiseerde trial.
Ten aanzien van het adequaat beoordelen van OCT afbeeldingen, dient een 
trainingsperiode in acht te worden genomen. In hoofdstuk 2.2 worden leercurves 
gepresenteerd die illustreren hoeveel OCT scans minimaal dienen te worden beoordeeld 
om foutpercentages binnen acceptabele marges te houden. Deze aantallen hangen af 
van vooraf ingestelde criteria voor acceptabele en onacceptabele foutenpercentages 
en afkapwaarden voor de definitie van een positieve test. De OCT-onderzoekers 
rapporteerden de mate van vertrouwen in hun diagnose op een 5-punts Likertschaal. 
In een scenario waarin OCT diagnoses met een score ≥ 2 (hoge verdenking op BCC of 
zekerheid over aanwezigheid van BCC) als positieve testuitslag werden gedefinieerd 
waren minimaal 183 oefenscans nodig om de foutenpercentages van onderzoekers 
binnen acceptabele grenzen te houden. In een scenario, waarin men bij de uitslag van 
OCT gebruikt om een punch biopsie achterwege te laten, ligt het meer voor de hand 
om alleen zekere OCT diagnoses (met scores 3 en 4) als een positieve OCT uitslag te 
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beschouwen. In dit geval is er meer training vereist en dienen minimaal 311 OCT scans 
te worden beoordeeld.
In hoofdstuk 3.1 presenteren we de resultaten van een non-inferiority gerandomiseerde 
studie waarin werd nagegaan of behandeling van het nodulaire BCC met curettage en 
imiquimod crème niet-inferieur is aan chirurgische excisie. Patiënten met een met biopt 
bewezen nodulair BCC werden via randomisatie in een van de twee behandelgroepen 
ingedeeld. Het primaire eindpunt was het percentage patiënten dat één jaar na het 
einde van de behandeling geen falen van de behandeling had. Behandelfalen werd 
gedefinieerd als de afwezigheid van residu tumor na 3 maanden of recidief na 1 jaar. Er 
werd een vooraf gespecificeerde non-inferioriteitsmarge van 8% gebruikt. Een daling in 
het succespercentage van maximaal 8% na behandeling met curettage en imiquimod-
crème werd als acceptabel beschouwd vanwege verwachte gunstige effecten op 
cosmetiek en patiënt-tevredenheid. In totaal werden 145 patiënten gerandomiseerd, 
waarvan 73 naar curettage en imiquimod crème en 72 naar chirurgische excisie. 
Het percentage recidiefvrije patiënten na 12 maanden was 86,3% voor curettage en 
imiquimod (63/73) en 100% voor excisie (72/72). De daling in succespercentage in de 
groep behandeld met curettage en imiquimod was 13.7% . De bovenste grens van het 
95% betrouwbaarheidsinterval (5.8%-21.6%) sluit een daling van meer dan 8% niet uit.
Niet-inferioriteit van curettage en imiquimod-crème aan chirurgische excisie kan 
derhalve niet worden geconcludeerd. In geselecteerde gevallen kunnen curettage en 
imiquimod een waardevolle behandelingsoptie zijn met de mogelijkheid om overmatig 
gebruik van excisies te voorkomen. Het kan echter chirurgische excisie niet vervangen.
Hoofdstuk 3.3 beschrijft de resultaten van een discrete choice experiment onder 
patiënten met een nodulair basaalcelcarcinoom. Een dergelijke vragenlijst geeft op 
basis van een aantal attributen, zoals cosmetiek, effectiviteit, wachttijden bijwerkingen, 
de patiënten keuzeopties tussen de twee behandelmogelijkheden door middel van 
verschillende levels (bijvoorbeeld percentage effectiviteit). De vragenlijst bestond uit 
12 verschillende keuzesets, elke keuzeset verschilt in de levels van de attributen. Per 
keuzeset werd aan patiënten gevraagd voor welke behandeling zij op dat moment de 
voorkeur hadden: curettage en imiquimod of excision. Patiënten kozen in 60% van de 
gevallen voor excisie en in 40% voor curettage en imiquimod. Het bleek dat cosmetische 
resultaten en bijwerkingen als de belangrijkste attributen werden gewaardeerd.
Tot slot hebben we een hoofdstuk (4.1 en 4.2) gewijd aan studies betreffende de 
behandeling met hedgehog pathway inhibitoren van basaalcelcarcinomen bij patiënten 
met het basaalcelnaevus syndroom (BCNS) en hoog-frequent BCC (HF-BCC) patiënten. 
BCNS is een syndroom veroorzaakt door een genetische afwijking die ervoor zorgt dat 
patiënten zeer veel basaalcelcarcinomen ontwikkelen en vaak al vanaf jonge leeftijd. 
De hedgehog pathway is essentieel in de ontwikkeling van een BCC en is geactiveerd in 
de meeste BCC’s. HF-BCC patiënten worden gedefinieerd als patiënten met minstens 
9 BCC excisies binnen een periode van 3 jaar. In de review in hoofdstuk 4.1 werd het 
overzicht gegeven van de huidige beschikbare kennis op het gebied van behandeling 
met hedgehog inhibitoren bij zowel BCNS patiënten als bij HF-BCC patiënten op het 
gebied van effectiviteit, veiligheid, tumor resistentie en recidief en kwaliteit van leven. 
Vooral bij deze patiënten lijkt de geregistreerde dosering niet optimaal en zal een 
patiënt vermoedelijk meer gebaat zijn bij een gepersonaliseerde behandeling.
Daarnaast beschreven we in hoofdstuk 4.2 een casus waarbij een met vismodegib 
behandelde patiënt met BCNS gerelateerde BCC’s resistent was voor de behandeling. 
Met genetisch onderzoek middels molecular inversion probes (MIP) op het 
tumormateriaal van zowel resistente als niet-resistente BCCs toonden we aan dat de 
oorzaak van deze resistentie vermoedelijk werd veroorzaakt door een mutatie in het gen 
smoothened, het gen dat normaliter wordt geremd door vismodegib. De therapeutische 
consequenties van resistente tumoren in patiënten met BCNS kwamen aan bod.
Hoofdstuk 5
Dit hoofdstuk besluit het proefschrift met een discussie en valorisatie waarin we de 
uitgevoerde onderzoeken bediscussiëren en het belang van het onderzoek voor de 
dagelijkse praktijk bespreken. 6
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SUMMARY
Basal cell carcinoma (BCC) is the most common form of skin cancer in the Netherlands 
with a life time risk of 20% to develop BCC. BCC generally can be categorized into three 
subtypes: superficial, nodular and infiltrative BCC. The subtype is of importance for the 
choice of optimal treatment. Although currently surgery is still the standard treatment, 
there is a trend toward less invasive diagnosis and treatment. More frequent use of 
non-invasive options in the current clinical setting, could result in a reduction of the 
workload for dermatologists, could be more patient friendly and might reduce costs 
of medical care. In dermatology, BCC is especially suited for a non-invasive approach 
since it is a type of skin cancer with an indolent growth character, a good prognosis 
and a very low risk of metastasis. This thesis focuses on minimally invasive methods for 
diagnosis and treatment of basal cell carcinoma, presented in 6 studies.
In chapter 1, the topics that will be discussed in this thesis are presented in a general 
introduction. The background, regarding epidemiology, origin, diagnosis and treatment 
of basal cell carcinoma and basal cell nevus syndrome is discussed and objectives of 
this thesis are described.
Non-invasive diagnostic strategies enable detailed investigation of skin tissue 
architecture and have the potential for identification and subtyping of basal cell 
carcinoma. One of these techniques is optical coherence tomography (OCT) as described 
in chapter 2. OCT is a safe laser light imaging technique that provides real-time, in vivo, 
cross-sectional images of lesions with a depth of about 1.5-2 mm. A scan probe is placed 
on the skin and an image of the lesion is made within 30 seconds. The speed and non-
invasive aspects makes OCT a very patient friendly method .
To evaluate the diagnostic value of OCT for identification and subtyping of BCC, we 
conducted a prospective cohort study in chapter 2.1 that enrolled 182 patients with 
a total of 250 lesions suspected of non-melanoma skin cancer or its precursors. Only 
patients requiring a biopsy for diagnosis were included. The first aim of the study was 
to determine whether OCT in addition to clinical images (cOCT) could increase the 
ability to distinguish between the presence and absence of BCC. The second aim was to 
determine whether the use of OCT in patients with BCC leads to an accurate diagnosis 
of the histological subtype. Confidence levels were recorded on a five-point scale, with 
score 0 indicating absence of BCC and scores 1-4 indicating increasing certainty of 
diagnosis. Diagnostic parameters were compared to histopathological diagnosis with 
the use of punch biopsy as gold standard.
cOCT increased the ability to discriminate between BCC and non-BCC. At patient level, 
the area under the curve increased from 85.6% for the clinical examination alone to 
91.2% for cOCT (p = 0.061) and at lesion level from 82.7% to 91.3% (p < 0.001) in favor of 
OCT. When a certainty on the 5-point scale 1-4 was defined as positive (some suspicion 
of BCC), specificity at the patient level increased from 47.5% (clinical study only) to 
76.8% (OCT) at comparable sensitivity (97.6% and 95.2%). cOCT slightly improved the 
ability to distinguish between superficial and non-superficial BCC subtypes and appears 
to be a valuable addition to clinical examination in the diagnosis and subtyping of BCC.
An additional analysis was performed to investigate whether a BCC diagnosis based on 
OCT is accurate enough to omit a punch biopsy in the future. In a clinical scenario, high 
confidence in the presence of BCC according to cOCT diagnosis could lead to a treatment 
decision without the need for verification of the histopathological diagnosis by punch 
biopsy. To evaluate the outcome of this potential scenario, the ability to predict BCC 
and subtype was evaluated within the group of cases in which BCC was diagnosed by 
cOCT with a confidence score of 4 (highest confidence). This level of certainty about 
the presence of BCC and the subtype according to cOCT was seen in 55 of 182 patients 
(30%). According to histopathology, 49 of these 55 patients (89.1%) indeed had a BCC 
and the remaining 6 diagnoses were benign conditions. The consequences of inaccurate 
diagnosis based on OCT in terms of over- and under treatment appear to be limited. 
However, the question of whether OCT-guided diagnosis and treatment of lesions with 
suspected BCC is possible without jeopardizing the prognosis of patients can only be 
answered with a randomized trial.
Accuracy of diagnosing BCC with OCT can improve with training. In chapter 2.2 learning 
curves are presented that illustrate the minimum number of OCT scans that should 
be assessed in order to keep error rates within acceptable margins. This number also 
depends on preset acceptable and unacceptable error rates and cut-off values  for the 
definition of a positive test. The OCT researchers reported their diagnosis on a 5-point 
scale, which allowed evaluation of their performance using different thresholds. When 
OCT diagnoses made with a confidence level ≥ 2 (either high suspicion or certainty of 
presence of BCC) was defined as test positive results, the minimally required number 
of training scans before achieving acceptable performance was 183 cases. In a scenario 
where a biopsy would be omitted if the OCT result is positive, it makes sense to use 
only certain OCT diagnoses (with scores 3 and 4) as positive. In this case, more training 
is required and a minimum number of 311 OCT scans must be assessed.
In chapter 3.1 a non-inferiority randomized trial is discussed which aimed to evaluate 
whether minimally invasive treatment of nodular basal cell carcinoma (nBCC) with 
curettage and imiquimod cream is non-inferior to standard treatment with surgical 
excision. Patients with a biopsy-proven nodular BCC were randomized into one of the 
two treatment groups. The primary endpoint was the percentage of patients without 
treatment failure one year after the end of treatment. A pre-specified non-inferiority 
margin of 8% was used. A decrease in the success rate of up to 8% after treatment 
with curettage and imiquimod cream was considered acceptable because of expected 
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beneficial effects on cosmetic outcomes and patient satisfaction. A total of 145 patients 
were randomized, of which 73 to curettage and imiquimod cream and 72 to surgical 
excision. The proportion of patients without treatment failure at 12 months was 86.3% 
for curettage and imiquimod (63/73) and 100% for excision (72/72). The reduction in 
success rate of curettage and imiquimod compared to excision was 13.7%. The upper 
limit of the 95% confidence interval (5.8% -21.6%) did not exclude a decrease of more 
than 8%. Non-inferiority of curettage and imiquimod cream cannot be concluded. 
However, given the still relatively high efficacy, curettage and imiquimod can be 
considered as a treatment option in selected cases or in a situation where it is beneficial 
to avoid overuse of excisions. However, it cannot replace surgical excision.
In addition, a discrete choice experiment was performed among patients with nodular 
BCC (chapter 3.2). The attributes used in this study that were marked as important for 
treatment were cosmetic outcomes, effectiveness, waiting time and side effects. The 
questionnaire consisted of 12 different choice sets, depending on different attribute 
levels. Per set, patients were asked what treatment they preferred in that specific 
choice set: curettage and imiquimod or surgical excision. In 60% of the cases, patients 
opted for excision and in 40% for curettage and imiquimod. It turned out that cosmetic 
results and adverse events were valued as the most important. These attributes were 
valued more than efficacy. 
In the last chapter (4.1 and 4.2) studies on hedgehog inhibitors in the treatment of basal 
cell carcinomas in patients with basal cell nevus syndrome (BCNS) and high-frequency 
BCC patients (HF-BCC patients) are discussed. BCNS is a syndrome caused by a genetic 
abnormality that causes patients to develop many basal cell carcinomas, often from an 
early age. The genetic defect is situated in the patched gene, a gene of the hedgehog 
pathway. The hedgehog pathway is not only defective in BCNS patients, but also 
essential in the development of a BCC and is activated in most BCCs. HF-BCC patients 
were defined as patients with at least 9 BCC surgeries in a 3 year time period. We 
reviewed the literature on hedgehog pathway inhibitors in BCNS and HF-BCC patients to 
provide an overview on efficacy, safety, tumor resistance and reoccurrence, and health-
related quality of life. Especially in patients with BCNS, the registered dose does not 
seem optimal and patients will probably benefit more from a personalized treatment.
In addition, in chapter 4.2 we described a case study in which with vismodegib treated 
patients with BCNS-related BCCs were resistant to the treatment. Genetic research 
using molecular inversion probes (MIP) on the tumor material of both resistant and non-
resistant BCCs showed that this resistance was probably caused by a mutation in the 
smoothened gene, the gene that is normally inhibited by vismodegib. The therapeutic 
consequences of resistant tumors in patients with BCNS were discussed.
Chapter 5
This chapter concludes the thesis with a discussion and valorization in which we discuss 
the research done and the importance of the research for daily practice.
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en het eindcoschap bij de Dermatologie in het RadboudUMC 
gedaan. Alvorens te starten aan haar promotieonderzoek 
bij de Dermatologie in het Maastricht UMC+, heeft zij 7 
maanden als ANIOS Ouderengeneeskunde gewerkt in Arnhem.
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- Commentary on “Long-Term Follow-Up Results of Topical Imiquimod Treatment in 
Basal Cell Carcinoma”. Jansen MHE, Sinx KAE, Kelleners-Smeets NWJ, Mosterd K. 
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- Vismodegib-resistant basal cell carcinomas in basal cell nevus syndrome: Clinical 
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Speel EM, Steijlen PM, van Geel M, Mosterd K. JAAD Case Rep. 2018 Apr 30;4(5):408-
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- Erythema annulare centrifigum bij een patiënt met polycythemia vera. K.A.E. Sinx 
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september 2015.
In november 2015 startte zij met haar promotieonderzoek. Kelly is sinds mei 2018 in 
opleiding tot dermatoloog in het Maastricht UMC+.
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ZonMw Grant Doelmatigheidsonderzoek 2018 Project: (Cost)-effectiveness of optical 
coherence tomography versus regular punch biopsy in the diagnosis and subtyping 
of basal cell carcinoma: a multi-center randomized non-inferiority trial. € 295.500,00
December 2016
Travel Grant, Fondation René Touraine, Paris. Mice studies for the treatment of 
basal cell carcinoma with imiquimod creme and diclofenac gel. Laboratory of prof. 
C. Blanpain, Brussels, Belgium. €1.650
April 2016
Grant Maurits en Anna de Kock stichting, Amsterdam. Support for the purchase 
of optical coherence tomography device. € 40.000
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October 2020
Oral presentation online: Surgery versus combined treatment with curettage and 
miquimod for treatment of nodular basal cell carcinoma(SCIN): 1-year results of a non-
inferiority, randomized controlled trial. European association of Dermato Oncology (EADO)
September 2018
Oral presentation: Optical Coherence Tomography for non-invasive diagnosis and 
subtyping of Basal Cell Carcinoma, a prospective cohort study. Congress European 
Academy of Dermatology and Venereology (EADV) Paris, France.
May 2017
Poster presentation: Vismodegib resistant basal cell carcinoma in Gorlin syndrome. 
Congress European association for Dermatology and Venereology. EADV Athens, Greece
Feb 2017
Oral presentation: Vismodegib resistant basal cell carcinoma in Gorlin syndrome, 
NVED 2017, Lunteren
2015
Poster presentation: Risk of photosensitive diuretics on developing skin malignancies 




Yes! Ook voor mij is het zover, het is af! Wat fijn om het dankwoord te kunnen schrijven, 
want met de hulp en steun van al deze mensen is mijn onderzoekerstijd super leuk en 
leerzaam geweest met een eindresultaat waarop ik tevreden terug kijk. Een aantal 
mensen wil ik in het bijzonder bedanken.
Mijn promotor Klara, bedankt voor jouw tomeloze inzet, support en stroom aan nieuwe 
ideeën. Ik kan niet anders zeggen dat juist door jou mijn boekje is geworden tot wat hij nu is.
Mijn promotor, Professor Steijlen, heel erg bedankt voor uw open en positieve blik. 
Tijdens het onderzoeksproces heeft dit veel opgeleverd, dus bedankt voor de kansen 
die u me heeft gegeven.
Mijn copromotor Patty, bedankt voor jouw grote betrokkenheid bij alle projecten. Jij 
was er altijd om kritisch naar dingen te kijken, waardoor ze alleen maar beter werden. 
Bedankt daarvoor!
Paranimfen en mijn liefste vriendinnen Florien en Jilske, wat ontzettend fijn dat jullie 
bij deze belangrijke dag aan mijn zijde staan. Wij kunnen heerlijk over alles kletsen, 
over leuke dingen in het leven, maar ook over minder leuke dingen. Ik weet dat ik altijd 
bij jullie terecht kan. Jullie staan super positief in het leven en zijn echte doorzetters. 
Het is zo fijn dat onze vriendschap ook na de studie in Nijmegen nog steeds zo hecht is 
gebleven! Super bedankt voor alle steun die jullie me geven.
Nicole, zo fijn dat jij ook onderdeel was van een aantal onderzoeksprojecten. Bedankt voor 
je input, je bent positief, maar ook rustig, patiëntbelangen staan in alles voor jou voorop.
Michel, dank voor je humor en rust. Wat had je veel geduld nodig om mij alles uit te 
leggen, maar nu weet ik toch maar gewoon wat MIPs zijn.
Marieke en Babette, fijn dat jullie zo mee hebt gedacht als het aankomt op vismodegib 
en basaalcelnaevus syndroom, dankzij jullie kennis is het artikel nog beter geworden.
Renske, zeker in de beginfase van mijn onderzoek kwam ik vaak bij je op bezoek in het 
lab. We konden altijd even gezellig bijkletsen voordat we hard aan het werk gingen. 
Dank voor het beantwoorden van al mijn vragen, ik kon altijd op je rekenen.
Brigitte, dank voor je betrokkenheid bij het discreet choice experiment project. Het is zo 
belangrijk om meningen, gedachten en voorkeuren van patiënten mee te nemen in onderzoek!
Graag wil ik van harte alle patiënten bedanken die aan al mijn onderzoeken hebben 
deelgenomen. Het is heel bijzonder hoe open jullie staan voor onderzoek en 
vooruitgang! Zonder jullie geen onderzoek!
Alle overige coauteurs wil ik ook van harte bedanken voor de hulp en meedenken bij 
de onderzoeken en artikelen: Aimée Arits, Ernst-Jan Speel, Guido Roemen.
Myrurgia en Véronique, hartelijk dank voor jullie bijdrage, niet alleen aan mijn artikelen, maar 
zeker ook gezien jullie alle biopten die in mijn onderzoeken voorkomen hebben beoordeeld.
Bedankt, iedereen van het secretariaat en de poli, maar in het bijzonder Nicole, Annie en 
Marie-Paul, voor het inplannen en coördineren van alle patiënten in mijn onderzoeken! 
Hierdoor kon ik met een gerust hart mijn trial-poli draaien.
Semi-artsen: Demie, Erwin en Gert-Jan, wat fijn dat jullie met zoveel enthousiasme en 
inzet hebben meegewerkt aan mijn projecten. Jullie hebben veel werk voor mij verzet.
Mede-promovendi, lieve Maud en Eva, we hebben heel wat tijd doorgebracht in ons 
onderzoekskamertje. De leuke en moeilijke momenten, maar daardoor konden we wel 
alles met elkaar delen. Dat was heel erg fijn! Wat zijn jullie ook een doorzetters! Nog 
even Eva en dan is het bij jou ook zover.
Lieve collega AIOS, wat is het ontzettend leuk om samen met jullie de opleiding te doen. 
We kunnen samen hard werken, maar hebben het ook super gezellig met elkaar! We 
make a good team!
Moniek, liefste vriendinnetje, wij kennen elkaar al zo lang en zijn eigen alleen maar 
closer geworden! De uithoeken van het land houden ons niet tegen. Heerlijk vind ik het 
altijd om met jou over alles te kunnen praten, een mooie wandeling te maken of samen 
carnaval te vieren in onze geboortestad Oosterhout. Je bent een ontzettend positief 
persoon en geeft echt kleur aan het leven. Jouw vrolijkheid en optimisme kan zelfs de 
meest chagrijnige persoon doen glimlachen.
Lieve schoonouders, bedank voor jullie interesse in het verloop van mijn promotie. 
Wat fijn dat jullie erbij zijn!
Lieve familie, hopelijk kan ik jullie met dit proefschrift wat beter laten zien wat ik de 
afgelopen jaren allemaal gedaan heb.
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Dankwoord
Liefste Bart, mijn kleine maar grootse broer, wij kunnen het altijd goed met elkaar vinden. 
Je bent heel zorgzaam, hebt een goede kritische blik en leuke humor. Ondanks dat we 
relatief ver van elkaar wonen, is die band nooit verloren geraakt. Onze werkgebieden 
verschillen totaal van elkaar, maar dat maakt de gesprekken altijd juist extra leuk.
Liefste papa en mama, ik wil jullie bedanken voor jullie nooit aflatende steun en 
vertrouwen. Niets is voor jullie teveel en ik kan altijd bij jullie terecht met leuke verhalen, 
maar ook als dingen niet zo goed gaan. Jullie zijn harde werkers, heel zorgzaam en staan 
super positief in het leven, mijn voorbeelden!
Liefste Olaf, met jouw energie en lekkere gekke humor is elke dag leuk. Wanneer ik 
dreig over te lopen, dan weet jij mij weer terug in de realiteit te brengen. Door jouw 
eigen drukke leven met studie en baan konden we elkaar ondersteunen en telkens 
weer motiveren om door te blijven gaan. Bij dezen wil ik jou nog eens extra bedanken 
voor jouw liefde, geduld en steun. Wauw je bent gewoon arts en tandarts! Kun je je al 
voorstellen hoeveel tijd we nu lekker samen over gaan hebben!?

